


The Whole Truth

Covid-19 Covid-19 Vaccines

Professor Jean-Bernard Fourtillan
Doctor Christian Tal Schaller
Docteur Serge Rader
Didier Rochard
Frédéric Chaumont

August 20, 2020

The calamities of the Vaccine they want to inject in your body




4 fragments of HIV1 which give to vaccinated people: **AIDS syndrom** and **Immunodeficiency** as a consequence

DNA sequences from the malaria germ which give **Malaria** to vaccinated people

157 additional DNA and protein sequences (see Patent US 8,243,718 B2), whose **presence** and **role** are **unexplained**

Nanoparticles which will allow **definitive control** of people vaccinated thanks to **5G**

The ChAdOx1 nCoV-19 vaccine they want to inject in your body contains



ChAdOx1 nCoV-19: Covid-19 coronavirus carried by the vector virus **ChAdOx1**

Nanoparticles described in Microsoft Patent PCT/US2019/038084, which will control you thanks to 5G

Disinfectants: either **Thimerosal** or **Formaldehyde** and antibiotics

COVID-19 is an artificial coronavirus made in France by the Institut Pasteur from natural Sars-CoV coronavirus

Covid-19 is the result of several genetic manipulations of a strain of Coronavirus Sars-CoV, associated with severe acute respiratory syndrome (SARS), resulting from a sample listed under the number 031589, collected from bronchoalveolar washings of Sars infected patients by scientists of Institut Pasteur, before 2003, at the French hospital in Hanoi (Vietnam)

- **1st Step: Sars-CoV-1** was produced by a first patent (2003: European Patent EP1694829 B1 and US Patent US 012.8224 A1) from Sars-CoV collected in Hanoi before 2003
- **2nd Step: Sars-CoV-2** was a continuation of the first US patent US 012.8224 A1, protected by the second US Patent US 8,243,718 B2 (2011), from Sars-CoV-1
- **3rd Step: Covid-19** was produced from Sars-Cov-2 by inserting into its genome 4 sequences of HIV1 (RNA AIDS virus)

Finally

Covid-19 was made in France by French scientists at the Institut Pasteur from natural Sars-CoV, then transferred to Wuhan where the People of Institut Pasteur released it, unbeknownst to scientists in the Wuhan laboratory and the Chinese government

When she says: "Covid-19 is not a Chinese virus", CHINA DOES NOT LIE!

From Sars-CoV to Covid-19



Sars-CoV

Collected, before 2003, at French hospital of Hanoi,
by Institut Pasteur (sample n° 031589)

1st Patent in 2003
Patent EP 1 694 829 B1
Patent US 012.8224 A1

**1 DNA sequence of 29746 nucleotides
+ 157 DNA and PRT sequences
inserted into RNA genome of Sars-CoV**



Sars-CoV1



Frédéric Tangy

2nd Patent in 2011
Patent US 8,243,718 B2

CONTINUATION OF
Patent EP 1 694 829 B1
Patent US 012.8224 A1



Sars-CoV2



Frédéric Tangy

Insertion carried out
at the Institut Pasteur
between 2011 and 2015


**Insertion of 4 fragments of HIV1,
corresponding to short segments
of amino acids found in
the gp 120 and the Gag of HIV1,
in the Sars-CoV2 genome**



Covid-19



Pierre Charneau



Frédéric Tangy

Covid-19: an artificial virus made in France

(19)



(11)

EP 1 694 829 B1

(12)

FASCICULE DE BREVET EUROPEEN

(45) Date de publication et mention de la délivrance du brevet:
04.08.2010 Bulletin 2010/31

(51) Int Cl.:
C12N 7/00 (2006.01)

(21) Numéro de dépôt: **04805625.3**

(86) Numéro de dépôt international:
PCT/FR2004/003106

(22) Date de dépôt: **02.12.2004**

(87) Numéro de publication internationale:
WO 2005/056584 (23.06.2005 Gazette 2005/25)

(54) **NOUVELLE SOUCHE DE CORONAVIRUS ASSOCIE AU SRAS ET SES APPLICATIONS.**

NEUER MIT SARS VERBUNDEN CORONAVIRUS STAMM UND SEINE VERWENDUNGEN
NOVEL STRAIN OF SARS-ASSOCIATED CORONAVIRUS AND APPLICATIONS THEREOF

(84) Etats contractants désignés:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

(30) Priorité: **02.12.2003 FR 0314151**
02.12.2003 FR 0314152

(43) Date de publication de la demande:
30.08.2006 Bulletin 2006/35

(60) Demande divisionnaire:
10005885.8

(73) Titulaires:

- **INSTITUT PASTEUR**
75724 Paris Cedex 15 (FR)
- **CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)**
75794 Paris Cedex 16 (FR)
- **UNIVERSITE PARIS VII**
75251 Paris Cedex 05 (FR)

(72) Inventeurs:

- **VAN DER WERF, Sylvie**
F-91190 Gif-sur-yvette (FR)
- **ESCRIOU, Nicolas**
F-75014 Paris (FR)
- **CRESCENZO-CHAIGNE, Bernadette**
F-92200 Neuilly-sur-seine (FR)
- **MANUGUERRA, Jean-Claude**
F-75018 Paris (FR)
- **KUNST, Frederik**
Inst. Pasteur
Bureau des Brevets et Inventions
75724 Paris Cedex 15 (FR)
- **CALLENDRET, Benoît**
F- 92000 Nanterre (FR)

- **BETTON, Jean-Michel**
75014 Paris (FR)
- **LORIN, Valérie**
92120 Montrouge (FR)
- **GERBAUD, Sylvie**
94100 Saint Maur Des Fosses (FR)
- **BURGUIERE, Ana Maria**
92140 Clamart (FR)
- **AZEBI, Saliha**
94400 Vitry-sur-seine (FR)
- **CHARNEAU, Pierre**
75005 Paris (FR)
- **TANGY, Frédéric**
93260 Les Lilas (FR)
- **COMBREDT, Chantal**
75017 Paris (FR)
- **DELAGNEAU, Jean-François**
78170 La Celle Saint Cloud (FR)
- **MARTIN, Monique**
92290 Chatenay Malabry (FR)

(74) Mandataire: **Marcadé, Véronique et al**
Cabinet Ores
36, rue de St Pétersbourg
75008 Paris (FR)

(56) Documents cités:

- **DATABASE EMBL 22 avril 2003 (2003-04-22), XP002294758 Database accession no. AY278489**
- **DATABASE EMBL 10 juin 2003 (2003-06-10), XP002294760 Database accession no. AY290752**
- **DATABASE UNIPROT 10 octobre 2003 (2003-10-10), XP002294761 Database accession no. P59595**

Il est rappelé que: Dans un délai de neuf mois à compter de la publication de la mention de la délivrance du brevet européen au Bulletin européen des brevets, toute personne peut faire opposition à ce brevet auprès de l'Office européen des brevets, conformément au règlement d'exécution. L'opposition n'est réputée formée qu'après le paiement de la taxe d'opposition. (Art. 99(1) Convention sur le brevet européen).

EP 1 694 829 B1



(11) **EP 1 694 829 B1**

(12) **FASCICULE DE BREVET EUROPEEN**

- (45) Date de publication et mention de la délivrance du brevet: **04.08.2010 Bulletin 2010/31**
- (21) Numéro de dépôt: **04805625.3**
- (22) Date de dépôt: **02.12.2004**
- (51) Int Cl.: **C12N 7/00 (2006.01)**
- (86) Numéro de dépôt international: **PCT/FR2004/003106**
- (87) Numéro de publication internationale: **WO 2005/056584 (23.06.2005 Gazette 2005/25)**

(54) **NOUVELLE SOUCHE DE CORONAVIRUS ASSOCIE AU SRAS ET SES APPLICATIONS.**

NEUER MIT SARS VERBUNDEN CORONAVIRUS STAMM UND SEINE VERWENDUNGEN
NOVEL STRAIN OF SARS-ASSOCIATED CORONAVIRUS AND APPLICATIONS THEREOF

- (84) Etats contractants désignés:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR
- (30) Priorité: **02.12.2003 FR 0314151**
02.12.2003 FR 0314152
- (43) Date de publication de la demande: **30.08.2006 Bulletin 2006/35**
- (60) Demande divisionnaire: **10005885.8**
- (73) Titulaires:
• INSTITUT PASTEUR
75724 Paris Cedex 15 (FR)
• CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
75794 Paris Cedex 16 (FR)
• UNIVERSITE PARIS VII
75251 Paris Cedex 05 (FR)
- (72) Inventeurs:
• VAN DER WERF, Sylvie
F-91190 Gif-sur-yvette (FR)
• ESCRIOU, Nicolas
F-75014 Paris (FR)
• CRESCENZO-CHAIGNE, Bernadette
F-92200 Neuilly-sur-seine (FR)
• MANUGUERRA, Jean-Claude
F-75018 Paris (FR)
• KUNST, Frederik,
Inst. Pasteur
Bureau des Brevets et Inventions
75724 Paris Cedex 15 (FR)
• CALLENDRET, Benoit
F- 92000 Nanterre (FR)
- BETTON, Jean-Michel**
75014 Paris (FR)
• LORIN, Valérie
92120 Montrouge (FR)
• GERBAUD, Sylvie
94100 Saint Maur Des Fosses (FR)
• BURGUIERE, Ana Maria
92140 Clamart (FR)
• AZEBI, Saliha
94400 Vitry-sur-seine (FR)
• CHARNEAU, Pierre
75005 Paris (FR)
• TANGY, Frédéric
93260 Les Lilas (FR)
• COMBREDT, Chantal
75017 Paris (FR)
• DELAGNEAU, Jean-François
78170 La Celle Saint Cloud (FR)
• MARTIN, Monique
92290 Chatenay Malabry (FR)
- (74) Mandataire: **Marcadé, Véronique et al**
Cabinet Ores
36, rue de St Pétersbourg
75008 Paris (FR)
- (56) Documents cités:
• DATABASE EMBL 22 avril 2003 (2003-04-22), XP002294758 Database accession no. AY278489
• DATABASE EMBL 10 juin 2003 (2003-06-10), XP002294760 Database accession no. AY290752
• DATABASE UNIPROT 10 octobre 2003 (2003-10-10), XP002294761 Database accession no. P59595

Il est rappelé que: Dans un délai de neuf mois à compter de la publication de la mention de la délivrance du brevet européen au Bulletin européen des brevets, toute personne peut faire opposition à ce brevet auprès de l'Office européen des brevets, conformément au règlement d'exécution. L'opposition n'est réputée formée qu'après le paiement de la taxe d'opposition. (Art. 99(1) Convention sur le brevet européen).

EP 1 694 829 B1

Page 3 of European Patent EP 1 694 829 B1

EP 1 694 829 B1

Description

[0001] La présente invention est relative à une nouvelle souche de coronavirus associé au syndrome respiratoire aigu sévère (SRAS), issue d'un prélèvement répertorié sous le n° 031589 et prélevé à Hanoi (Vietnam), à des molécules d'acide nucléique issues de son génome, aux protéines et peptides codés par lesdites molécules d'acide nucléique ainsi qu'à leurs applications, notamment en tant que réactifs de diagnostic et/ou comme vaccin.

[0002] Le coronavirus est un virus à ARN monocaténaire, de polarité positive, d'approximativement 30 kilobases qui se réplique dans le cytoplasme des cellules hôtes ; l'extrémité 5' du génome a une structure en coiffe et l'extrémité 3' comporte une queue polyA. Ce virus est enveloppé et comprend, à sa surface, des structures péplomériques dénommées spicules.



US 20070128224A1

(19) **United States**

(12) **Patent Application Publication**
Van Der Werf et al.

(10) **Pub. No.: US 2007/0128224 A1**
(43) **Pub. Date: Jun. 7, 2007**

(54) **NOVEL STRAIN OF SARS-ASSOCIATED
CORONAVIRUS AND APPLICATIONS
THEREOF**

(76) Inventors: **Sylvie Van Der Werf**, Gif-Sur-Yvette (FR); **Nicolas Escriou**, Paris (FR); **Bernadette Crescenzo-Chaigne**, Neuilly-Sur-Seine (FR); **Jean-Claude Manuguerra**, Paris (FR); **Frederick Kunst**, Paris (FR); **Benoit Callendret**, Nanterre (FR); **Jean-Michel Betton**, Paris (FR); **Valerie Lorin**, Montrouge (FR); **Sylvie Gerbaud**, Saint-Maur-Des-Fosses (FR); **Ana Maria Burguiere**, Clamart (FR); **Saliha Azebi**, Vitry-Sur-Seine (FR); **Pierre Charneau**, Paris (FR); **Frederic Tangy**, Les Lilas (FR); **Chantal Combredet**, Paris (FR); **Jean-Francois Delagneau**, La Celle Saint Cloud (FR); **Monique Martin**, Chatenay Malabry (FR)

Correspondence Address:
**FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER
LLP
901 NEW YORK AVENUE, NW
WASHINGTON, DC 20001-4413 (US)**

(21) Appl. No.: **10/581,356**

(22) PCT Filed: **Dec. 2, 2004**

(86) PCT No.: **PCT/FR04/03106**

§ 371(c)(1),
(2), (4) Date: **Feb. 8, 2007**

(30) **Foreign Application Priority Data**

Dec. 2, 2003 (FR)..... 0314151
Dec. 2, 2003 (FR)..... 0314152

Publication Classification

(51) **Int. Cl.**
A61K 39/215 (2006.01)
C12Q 1/70 (2006.01)
C07H 21/04 (2006.01)
C07K 14/165 (2006.01)
C07K 16/10 (2006.01)
C12N 5/06 (2006.01)
(52) **U.S. Cl.** **424/221.1**; 435/5; 435/69.3;
435/326; 435/456; 530/350;
530/388.3; 536/23.72; 977/802

(57) **ABSTRACT**

The invention relates to a novel strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from a sample collected in Hanoi (Vietnam), reference number 031589, nucleic acid molecules originating from the genome of same, proteins and peptides coded by said nucleic acid molecules and, more specifically, protein N and the applications thereof, for example, as diagnostic reagents and/or as a vaccine.



US008343718B2

(12) **United States Patent**
Van Der Werf et al.

(10) **Patent No.:** **US 8,343,718 B2**
(45) **Date of Patent:** **Jan. 1, 2013**

(54) **STRAIN OF SARS-ASSOCIATED CORONAVIRUS AND APPLICATIONS THEREOF**

(75) Inventors: **Sylvie Van Der Werf**, Gif-Sur-Yvette (FR); **Nicolas Escriou**, Paris (FR); **Bernadette Crescenzo-Chaigne**, Neuilly-Sur-Seine (FR); **Jean-Claude Manuguerra**, Paris (FR); **Frederik Kunst**, Paris (FR); **Benoît Callendret**, Nanterre (FR); **Jean-Michel Betton**, Paris (FR); **Valérie Lorin**, Montrouge (FR); **Sylvie Gerbaud**, Saint-Maur-Des-Fosses (FR); **Ana Maria Burguiere**, Clamart (FR); **Saliha Azebi**, Vitry-Sur-Seine (FR); **Pierre Charneau**, Paris (FR); **Frédéric Tangy**, Les Lilas (FR); **Chantal Combredet**, Paris (FR); **Jean-François Delagneau**, La Celle Saint Cloud (FR); **Monique Martin**, Chatenay Malabry (FR)

(73) Assignees: **Institut Pasteur**, Paris (FR); **Centre National de la Recherche Scientifique**, Paris (FR); **Universite Paris 7**, Paris (FR)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **12/754,908**
(22) Filed: **Apr. 6, 2010**

(65) **Prior Publication Data**
US 2011/0065089 A1 Mar. 17, 2011

Related U.S. Application Data
(60) Division of application No. 10/581,356, filed on Feb. 8, 2007, now Pat. No. 7,736,850, which is a continuation of application No. PCT/FR2004/003106, filed on Dec. 2, 2004.

(30) **Foreign Application Priority Data**
Dec. 2, 2003 (FR) 03 14151
Dec. 2, 2003 (FR) 03 14152

(51) **Int. Cl.**
C12Q 1/70 (2006.01)
G01N 33/53 (2006.01)
G01N 33/542 (2006.01)
G01N 33/00 (2006.01)

(52) **U.S. Cl.** **435/5; 435/7.1; 435/7.9; 435/7.92; 435/7.94; 435/7.95**

(58) **Field of Classification Search** None
See application file for complete search history.

(56) **References Cited**
U.S. PATENT DOCUMENTS
2003/0008332 A1* 1/2003 Ryan et al. 435/7.22
2005/0100883 A1* 5/2005 Wang et al. 435/5

OTHER PUBLICATIONS

Azcona-Olivera et al. Generation of Antibodies Reactive with Fumonisin B1, B2, and B3 by Using Cholera Toxin as the Carrier-Adjuvant. Applied and Environmental Microbiology, Jan. 1992, vol. 58, No. 1, pp. 169-173.*
Li et al. The Epitope Study on the SARS-CoV Nucleocapsid Protein. Genomics, Proteomics and Bioinformatics, Aug. 2003, vol. 1, No. 3, pp. 198-206.*
Wirtz et al. Comparative testing of monoclonal antibodies against Plasmodium falciparum sporozoites for ELISA development. Bulletin of the World Health Organization 1987, vol. 65, No. 1, pp. 39-45.*
Voller et al. Enzyme immunoassays with special reference to ELISA techniques. Journal of Clinical Pathology 1978, vol. 31, p. 507-520.*
Kemeny et al. Development of a semi-quantitative enzyme-linked immunosorbent assay (ELISA) for detection of human IgG subclass antibodies. Journal of Immunologica Methods 1987, Vol.*
Li et al. Detection and analysis of SARS coronavirus-specific antibodies in sera from non-Sars children. Di Yi Jun Yi Da Xue Xue Bao (Journal of the First Military Medical University) Oct. 2003, vol. 23, No. 10, pp. 1085-1087.*
Database EMBL, XP002294758, Database accession No. AY278489, "EMBL Sequence Version Archive", pp. 1-7, (Apr. 22, 2003).
Database EMBL, XP002294760, Database accession No. AY290752, "EMBL Sequence Version Archive", pp. 1-2, (Jun. 10, 2003).
Database UNIPROT, XP002294761, Database accession No. P59595, pp. 1-4, "Human Coronavirus", (Oct. 10, 2003).
Marra, et al., "The Genome Sequence of the SARS-Associated Coronavirus", Science, American Association for the Advancement of Science, vol. 300, No. 5624, pp. 1399-1404, (May 30, 2003).
Che, et al., "Rapid and Efficient Preparation of Monoclonal Antibodies Against SARS-Associated Coronavirus Nucleocapsid Protein by Immunizing Mice", Di Yi Junyi Daxue Xuebao—Academic Journal of First Medical College of PLA, Gain Kan Bianjishi, Guangzhou, CN, vol. 23, No. 7, pp. 640-642, (Jul. 2003).
Wang, et al., "Assessment of Immunoreactive Synthetic Peptides from the Structural Proteins of Severe Acute Respiratory Syndrome Coronavirus", Clinical Chemistry, American Association for Clinical Chemistry, Winston, US, vol. 49, No. 12, pp. 1989-1996, (Nov. 13, 2003).
Shi, et al., "Diagnosis of Severe Acute Respiratory Syndrome (SARS) by Detection of SARS Coronavirus Nucleocapsid Antibodies in an Antigen-Capturing Enzyme-Linked Immunosorbent Assay", Journal of Clinical Microbiology, Washington, DC, US, vol. 41, No. 12, pp. 5781-5782, (Dec. 2003). Liu, et al., "The C-Terminal Portion of the Nucleocapsid Protein Demonstrates SARS-CoV Antigenicity", Genomics, Proteomics and Bioinformatics, vol. 1, No. 3, pp. 193-197, (Aug. 2003).
Poon, et al., "Rapid Diagnosis of a Coronavirus Associated with Severe Acute Respiratory Syndrome (SARS)", Clinical Chemistry, American Association for Clinical Chemistry, Winston, US, vol. 49, No. 6, Pt. 1, pp. 953-955, (Jun. 2003).

* cited by examiner
Primary Examiner — Louise Humphrey
(74) *Attorney, Agent, or Firm* — Finnegan, Henderson, Farabow, Garrett & Dunner L.L.P.

(57) **ABSTRACT**
The invention relates to a novel strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from a sample collected in Hanoi (Vietnam), reference number 031589, nucleic acid molecules originating from the genome of same, proteins and peptides coded by said nucleic acid molecules and, more specifically, protein N and the applications thereof, for example, as diagnostic reagents and/or as a vaccine.

8 Claims, 116 Drawing Sheets

The proof that the 3 patents EP 1 694 829 B1, US 012.8224 A1, and US 8,243,718 B2, filed by the Institut Pasteur in 2003 and 2011, were intended to protect the manufacture of Tests and Vaccines, are mentioned in the abstracts of these patents

Page 3 of European Patent EP 1 694 829 B1

EP 1 694 829 B1

Description

[0001] La présente invention est relative à une nouvelle souche de coronavirus associé au syndrome respiratoire aigu sévère (SRAS), issue d'un prélèvement répertorié sous le n° 031589 et prélevé à Hanoi (Vietnam), à des molécules d'acide nucléique issues de son génome, aux protéines et peptides codés par lesdites molécules d'acide nucléique ainsi qu'à leurs applications, notamment en tant que réactifs de diagnostic et/ou comme vaccin.

[0002] Le coronavirus est un virus à ARN monocaténaire, de polarité positive, d'approximativement 30 kilobases qui se réplique dans le cytoplasme des cellules hôtes ; l'extrémité 5' du génome a une structure en coiffe et l'extrémité 3' comporte une queue polyA. Ce virus est enveloppé et comprend, à sa surface, des structures péplomériques dénommées spicules.

Page 1 of American Patent US 012.8224 A1

(57)

ABSTRACT

The invention relates to a novel strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from a sample collected in Hanoi (Vietnam), reference number 031589, nucleic acid molecules originating from the genome of same, proteins and peptides coded by said nucleic acid molecules and, more specifically, protein N and the applications thereof, for example, as diagnostic reagents and/or as a vaccine.

8 Claims, 116 Drawing Sheets

Page 1 of American Patent US 8,243,718 B2

(57)

ABSTRACT

The invention relates to a novel strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from a sample collected in Hanoi (Vietnam), reference number 031589, nucleic acid molecules originating from the genome of same, proteins and peptides coded by said nucleic acid molecules and, more specifically, protein N and the applications thereof, for example, as diagnostic reagents and/or as a vaccine.

From Covid-19 to ChAdOx1 n-CoV-19 Vaccine

Covid-19

Insertion of Covid-19 genome into the genome of a viral vector
(ChAdOx1 Chimpanzee DNA adenovirus)

Jenner Institute



Adrian Hill
Director of Jenner Institute

Covid-19 vaccine


ChAdOx1 nCoV-19 (GSK, Sanofi)

Insertion of tracing nanoparticles in the vaccine vial to be injected into the human body together with the vaccine

US Patent WO 2020/060606 A1
PCT/US20 19/038084 Microsoft

Final vaccine

NANOPARTICLES OF Covid-19 VACCINES
CRYPTOCURRENCY SYSTEM USING BODY ACTIVITY DATA



Bill Gates

Nanoparticles they want to inject in your body together with ChAdOx1 nCovid-19 Vaccine

100

Satellites for 5G

Task server



110

Cryptocurrency System

150

Communication Network
5G relays

120

Nanoparticles

injected together with vaccine

Vaccinated people



145

Sensor
Nanoparticles

140


User Device
Mobile phones

130



Bill Gates

Trombinoscope of the promoters of the ChAdOx1 nCoV-19 vaccine



Bill Gates



Emmanuel Macron



Jacques Attali




Agnès Buzyn



Yves Lévy



Olivier Véran



Jérôme Salomon



Dominique Martin



Tedros Adhanom
Ghebreyesus



Anthony Fauci



Frédéric Tangy



Adrian Hill

PRELUDE

To fully **control** and **enslave** the **world's population**, by monitoring and weakening it, the leaders of the New World Order had **nothing better** at their disposal **than a Vaccine**. With this diabolical intention, they had many genetic manipulations carried out, on the genome of the Sars-CoV coronavirus responsible for the SARS epidemic that occurred between 2002 and 2003 in Asia.

The **Covid-19** coronavirus, **different from Sars-CoV2**, is an **artificial virus** that is the result of **many genetic manipulations** carried out on the **natural Sars-CoV** coronavirus, which successively led to 3 artificial coronaviruses **Sars-CoV1**, **Sars-CoV2**, and **Covid-19**, described in 3 patents filed by the Institut Pasteur, which provide their intellectual protections

In its genome, **Covid-19 carries**, among other calamities, **4 RNA fragments from HIV**, the AIDS virus, which corresponds to short segments of amino acids found in gp120 and Gag of HIV-1, which will place all vaccinated people in immunodeficiency, and **DNA fragments from the malaria germ**.

Men around the world must open their eyes and understand that **the natural Sars-CoV** coronavirus **poses no danger to humanity**, unlike **artificial Covid-19**. **Covid-19 helped spark a false pandemic**, and **spread fear** across the world, **to make us accept the Covid-19 vaccines**.

Numerical tracing **nanoparticles** have been **added to the vials of the final Covid-19 vaccine (ChAdOx1 nCoV-19)**.

By seeking to vaccinate the entire world population, the promoters of the Covid-19 vaccines pursue **two objectives**:

- **Control the entire world population** after having vaccinated it, **thanks to the deployment of 5G**, because these vaccines contain **nanoparticles** which will allow the **identification** and **permanent control** of vaccinated individuals;
- **Limit the world's population**.

From Sars-CoV
to
Covid-19

Doctor Frédéric Tangy is the father of Covid-19



Doctor Frédéric Tangy


Director of Vaccine Innovation at the Institut Pasteur

Publications concernant les coronavirus et les vaccins

- 1- **2003**: Inventor in patents EP1694829 B1 and US 012.8224 A1
- 2- **2005**: Publication: Frédéric Tangy and Hussein Naim *Live attenuated Measles Vaccine as a Potential Multivalent Pediatric Vaccination Vector. VIRAL IMMUNOLOGY, Volume 18, Number 2, 2005, p 317-326* (voir [DOCUMENT 2](#))
- 3- **2011**: Inventor in patent US 8,343,718 B2
- 4- **2014**: Publication: Nicolas Escriou, Benoît Callendret, Valérie Lorin, Chantal Combredet, Philippe Marianneau, Michèle Février, Frédéric Tangy. *Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein*, in *Virology* 452–453, March, 2014, p 32-41 (voir [DOCUMENT 13](#))
- 5- **2020**: PARIS-MATCH article from April, 9-15, 2020 (voir [DOCUMENT 3](#))
- 6- **2020**: PARIS-MATCH article from May, 14-20, 2020 (voir [DOCUMENT 5](#))

Le docteur Frédéric Tangy est le père du Covid-19

Frédéric Tangy



From Sars-CoV to Sars-CoV1

Before 2003



Institut Pasteur



Frédéric Tangy

**1 DNA sequence of 29746 nucleotides
+ 157 DNA and PRT sequences
inserted into RNA genome of Sars-CoV**

Sars-CoV



Sars-CoV1

Collected at French Hospital of Hanoi,
by Institut Pasteur (sample n° 031589)

**Patent EP 1 694 829 B1
Patent US 012.8224 A1**

First Patent US 2007/0128224 A1



US 20070128224A1

(19) **United States**

(12) **Patent Application Publication** (10) **Pub. No.: US 2007/0128224 A1**
Van Der Werf et al. (43) **Pub. Date: Jun. 7, 2007**

(54) **NOVEL STRAIN OF SARS-ASSOCIATED CORONAVIRUS AND APPLICATIONS THEREOF**

(76) Inventors: **Sylvie Van Der Werf**, Gif-Sur-Yvette (FR); **Nicolas Escriou**, Paris (FR); **Bernadette Crescenzo-Chaigne**, Neuilly-Sur-Seine (FR); **Jean-Claude Manuguerra**, Paris (FR); **Frederick Kunst**, Paris (FR); **Benoit Callendret**, Nanterre (FR); **Jean-Michel Betton**, Paris (FR); **Valerie Lorin**, Montrouge (FR); **Sylvie Gerbaud**, Saint-Maur-Des-Fosses (FR); **Ana Maria Burguiere**, Clamart (FR); **Saliha Azebi**, Vitry-Sur-Seine (FR); **Pierre Charneau**, Paris (FR); **Frederic Tangy**, Les Lilas (FR); **Chantal Combredet**, Paris (FR); **Jean-Francois Delagneau**, La Celle Saint Cloud (FR); **Monique Martin**, Chatenay Malabry (FR)

Correspondence Address:
**FINNÉGAN, HENDERSON, FARABOW,
GARRETT & DUNNER
LLP
901 NEW YORK AVENUE, NW
WASHINGTON, DC 20001-4413 (US)**

(21) Appl. No.: **10/581,356**

(22) PCT Filed: **Dec. 2, 2004**

(86) PCT No.: **PCT/FR04/03106**

§ 371(c)(1),
(2), (4) Date: **Feb. 8, 2007**

(30) **Foreign Application Priority Data**

Dec. 2, 2003 (FR)..... 0314151
Dec. 2, 2003 (FR)..... 0314152

Publication Classification

(51) **Int. Cl.**
A61K 39/215 (2006.01)
C12Q 1/70 (2006.01)
C07H 21/04 (2006.01)
C07K 14/165 (2006.01)
C07K 16/10 (2006.01)
C12N 5/06 (2006.01)

(52) **U.S. Cl.** **424/221.1; 435/5; 435/69.3; 435/326; 435/456; 530/350; 530/388.3; 536/23.72; 977/802**

(57) **ABSTRACT**

The invention relates to a novel strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from a sample collected in Hanoi (Vietnam), reference number 031589, nucleic acid molecules originating from the genome of same, proteins and peptides coded by said nucleic acid molecules and, more specifically, protein N and the applications thereof, for example, as diagnostic reagents and/or as a vaccine.

Patent US 2007/0128224 A1

Claims 1

US 2007/0128224 A1

1

NOVEL STRAIN OF SARS-ASSOCIATED CORONAVIRUS AND APPLICATIONS THEREOF

[0001] The present invention relates to a novel strain of severe acute respiratory syndrome (SARS)-associated coronavirus derived from a sample recorded under No. 031589 and collected in Hanoi (Vietnam), to nucleic acid molecules derived from its genome, to the proteins and peptides encoded by said nucleic acid molecules and to their applications, in particular as diagnostic reagents and/or as vaccine.

[0002] Coronavirus is a virus containing single-stranded RNA, of positive polarity, of approximately 30 kilobases which replicates in the cytoplasm of the host cells; the 5' end of the genome has a capped structure and the 3' end contains a polyA tail. This virus is enveloped and comprises, at its surface, peplomeric structures called spicules.

Patent US 2007/0128224 A1

Claims 2

[0020] The subject of the present invention is therefore an isolated or purified strain of severe acute respiratory syndrome-associated human coronavirus, characterized in that its genome has, in the form of complementary DNA, a serine codon at position 23220-23222 of the gene for the S protein or a glycine codon at position 25298-25300 of the gene for ORF3, and an alanine codon at position 7918-7920 of ORF1a or a serine codon at position 26857-26859 of the gene for the M protein, said positions being indicated in terms of reference to the Genbank sequence AY274119.3.

[0021] According to an advantageous embodiment of said strain, the DNA equivalent of its genome has a sequence corresponding to the sequence SEQ ID No: 1; this coronavirus strain is derived from the sample collected from the bronchoalveolar washings from a patient suffering from SARS, recorded under the No. 031589 and collected at the Hanoi (Vietnam) French hospital.

[0022] In accordance with the invention, said sequence SEQ ID No: 1 is that of the deoxyribonucleic acid corresponding to the ribonucleic acid molecule of the genome of the isolated coronavirus strain as defined above.

Insertion of a first DNA sequence (29746 nucleotides) in the genome of Sars-Cov collected in the French hospital at Hanoi (Vietnam)

Patent Application Publication Jun. 7, 2007 Sheet 14 of 116 US 2007/0128224 A1

```

                                     >< XhoII
                                     >< Sau3AI
                                     >< NdeII
>< ScrFI
>< MvaI          > < TthHB8I
>< EcoRII        > < TaqI          >< MflI
>< Ecl136I      >< Sau3AI        >< MboI
>< DsaV         >< NdeII        >< DpnII
>< BstOI        >< MboI>< MnlI>< DpnI
>< BstNI        >< DpnII        >< BstYI
>< BsiLI        >< DpnI         >< BspAI
>< BsaJI        >< BspAI         >< Bsp143I
>< ApyI         >< Bsp143I>< BglII
ATATTAGGTT TTTACCTACC CAGGAAAAGC CAACCAACCT CGATCTCTTG TAGATCTGTT CTCTAAACGA
      10          20          30          40          50          60          70
```

Patent Application Publication Jun. 7, 2007 Sheet 83 of 116 US 2007/0128224 A1

```

CGAGGGTACA GTGAATAATG CTAGGGAGAG CTGCCTATAT GGAAGAGCCC TAATGTGTAA AATTAATTTT
      29620      29630      29640      29650      29660      29670      29680

                                     >< Tru9I   >< DdeI
                                     >< MseI   >< BfrI
                                     >< NlaIII  > < AluI
AGTAGTGCTA TCCCCATGTG ATTTTAATAG CTTCTTAGGA GAATGACAAA AAAAAAAAAA AAAAAA
      29690      29700      29710      29720      29730      29740
```

Listing of the 158 DNA and Protein sequences inserted, by Pasteur Institute people, into the Sars-CoV coronavirus, taken, in 2003, from a patient at the French hospital in Hanoi

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 158

<210> SEQ ID NO 1

<211> LENGTH: 29746

<212> TYPE: DNA

<213> ORGANISM: CORONAVIRUS

**Sars-CoV1: SEQUENCE 1
DNA**

<400> SEQUENCE: 1

```

atattaggtt tttacctacc caggaaaagc caaccaacct cgatctcttg tagatctgtt      60
ctctaaacga actttaaagt ctgtgtagct gtcgctcggc tgcattgcta gtgcacctac      120

atctcacata gcaatcttta atcaatgtgt aacattaggg aggacttgaa agagccacca      29580
cattttcacc gaggccacgc ggagtacgat cgagggtaca gtgaataatg ctaggagagag      29640
ctgcctatat ggaagagccc taatgtgtaa aattaatttt agtagtgcta tccccatgtg      29700
attttaatag cttcttagga gaatgacaaa aaaaaaaaaa aaaaaa                      29746
    
```

<212> TYPE: DNA

<213> ORGANISM: CORONAVIRUS

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (89)..(3853)

<223> OTHER INFORMATION:

**Sars-CoV1: SEQUENCE 2
DNA**

<400> SEQUENCE: 2

```

ttctcttctg gaaaaaggta ggcttatcat tagagaaaac aacagagttg tggtttcaag      60
tgatattctt gttaacaact aaacgaac atg ttt att ttc tta tta ttt ctt      112
                               Met Phe Ile Phe Leu Leu Phe Leu
                               1                               5

act ctc act agt ggt agt gac ctt gac cgg tgc acc act ttt gat gat      160
Thr Leu Thr Ser Gly Ser Asp Leu Asp Arg Cys Thr Thr Phe Asp Asp
10                               15                               20

ctc aag ggt gca tgc tct tgt ggt tct tgc tgc aag ttt gat gag      3808
Leu Lys Gly Ala Cys Ser Cys Gly Ser Cys Cys Lys Phe Asp Glu
1230                               1235                               1240

gat gac tct gag cca gtt ctc aag ggt gtc aaa tta cat tac aca      3853
Asp Asp Ser Glu Pro Val Leu Lys Gly Val Lys Leu His Tyr Thr
1245                               1250                               1255

taaacgaact tatggatttg tttatgagat tttttactct tggatcaatt actgcacagc      3913
cagtaaaaat tgacaatgct tctcctgcaa gt                                      3945
    
```

**Listing of the 158 DNA and Protein sequences inserted, by Pasteur Institute people,
into the Sars-CoV coronavirus, taken, in 2003, from a patient at the French hospital in Hanoi
Following up**

<210> SEQ ID NO 3
 <211> LENGTH: 1255
 <212> TYPE: PRT
 <213> ORGANISM: CORONAVIRUS

Sars-CoV1: SEQUENCE 3

PRT

<400> SEQUENCE: 3

Met Phe Ile Phe Leu Leu Phe Leu Thr Leu Thr Ser Gly Ser Asp Leu
 1 5 10 15

Asp Arg Cys Thr Thr Phe Asp Asp Val Gln Ala Pro Asn Tyr Thr Gln
 20 25 30

Met Thr Ser Cys Cys Ser Cys Leu Lys Gly Ala Cys Ser Cys Gly
 1220 1225 1230

Ser Cys Cys Lys Phe Asp Glu Asp Asp Ser Glu Pro Val Leu Lys
 1235 1240 1245

Gly Val Lys Leu His Tyr Thr
 1250 1255

<210> SEQ ID NO 16
 <211> LENGTH: 708
 <212> TYPE: DNA
 <213> ORGANISM: CORONAVIRUS
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (41)..(703)
 <223> OTHER INFORMATION:

Sars-CoV1: SEQUENCE 16

DNA

<400> SEQUENCE: 16

tattattatt attctgtttg gaactttaac attgcttacc atg gca gac aac ggt 55
 Met Ala Asp Asn Gly
 1 5

act att acc gtt gag gag ctt aaa caa ctc ctg gaa caa tgg aac cta 103
 Thr Ile Thr Val Glu Glu Leu Lys Gln Leu Leu Glu Gln Trp Asn Leu
 10 15 20

<210> SEQ ID NO 28
 <211> LENGTH: 39
 <212> TYPE: PRT
 <213> ORGANISM: CORONAVIRUS

Sars-CoV1: SEQUENCE 28

PRT

<400> SEQUENCE: 28

Met Lys Leu Leu Ile Val Leu Thr Cys Ile Ser Leu Cys Ser Cys Ile
 1 5 10 15

Cys Thr Val Val Gln Arg Cys Ala Ser Asn Lys Pro His Val Leu Glu

Listing of the 158 DNA and Protein sequences inserted, by Pasteur Institute people, into the Sars-CoV coronavirus, taken, in 2003, from a patient at the French hospital in Hanoi
Following up

Sars-CoV1: SEQUENCE 31
DNA

<210> SEQ ID NO 31
<211> LENGTH: 21221
<212> TYPE: DNA
<213> ORGANISM: CORONAVIRUS

<400> SEQUENCE: 31

atggagagcc ttgttcttgg tgtcaacgag aaaacacacg tccaactcag tttgcctgtc 60
cttcaggta gagacgtgct agtgcggtggc ttcggggact ctgtggaaga ggccctatcg 120
gaggcacgtg aacacctcaa aaatggcact tgtggtctag tagagctgga aaaaggcgta 180
ctgccccagc ttgaacagcc ctatgtgttc attaaacggt ctgatgcctt aagcaccaat 240

ctaactacat tttctggagg aacacaaatc ctatccagtt gtcttctctat tcaactctttg 21060
acatgagcaa atttctcttt aaattaagag gaactgctgt aatgtctctt aaggagaatc 21120
aaatcaatga tatgatttat tctcttctgg aaaaaggtag gcttatcatt agagaaaaca 21180
acagagttgt ggtttcaagt gatattcttg ttaacaacta a 21221

Sars-CoV1: SEQUENCE 46
DNA

<210> SEQ ID NO 46
<211> LENGTH: 1995
<212> TYPE: DNA
<213> ORGANISM: CORONAVIRUS

<400> SEQUENCE: 46

tttgtgcact catactcgct tacagtaata aaactggttg cgagcttggt gatgtcagag 60
aaactatgac ccactcttcta cagcatgcta atttggaaac tgcaaagcga gttcttaatg 120

Sars-CoV1: SEQUENCE 55
DNA

<210> SEQ ID NO 55
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: N sens primer

<400> SEQUENCE: 55

cccatatgtc tgataatgga cccaatcaa ac

Listing of the 158 DNA and Protein sequences inserted, by Pasteur Institute people, into the Sars-CoV coronavirus, taken, in 2003, from a patient at the French hospital in Hanoi
Following up

<210> SEQ ID NO 61
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Antisens set 2 (28774-28759) primer

Sars-CoV1: SEQUENCE 61
DNA

<400> SEQUENCE: 61

cagtttcacc acctcc

<210> SEQ ID NO 69
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: artificial sequence

Sars-CoV1: SEQUENCE 69
PRT

<220> FEATURE:
<223> OTHER INFORMATION: M2-14 peptide

<400> SEQUENCE: 69

Ala Asp Asn Gly Thr Ile Thr Val Glu Glu Leu Lys Gln
1 5 10

<210> SEQ ID NO 73
<211> LENGTH: 410
<212> TYPE: DNA
<213> ORGANISM: CORONAVIRUS

Sars-CoV1: SEQUENCE 73
DNA

<400> SEQUENCE: 73

ttctccagac aacttcaaaa ttccatgagt ggagcttctg ctgattcaac tcaggcataa 60
acactcatga tgaccacaca aggcagatgg gctatgtaaa cgttttcgca attccgttta 120
cgatacatag tctactcttg tgcagaatga attctcgtaa ctaaacagca caagtaggtt 180

<210> SEQ ID NO 74
<211> LENGTH: 4382
<212> TYPE: PRT
<213> ORGANISM: CORONAVIRUS

Sars-CoV1: SEQUENCE 74
PRT

<400> SEQUENCE: 74

Met Glu Ser Leu Val Leu Gly Val Asn Glu Lys Thr His Val Gln Leu
1 5 10 15

Ser Leu Pro Val Leu Gln Val Arg Asp Val Leu Val Arg Gly Phe Gly
20 25 30

Listing of the 158 DNA and Protein sequences inserted, by Pasteur Institute people, into the Sars-CoV coronavirus, taken, in 2003, from a patient at the French hospital in Hanoi
Following up

<210> SEQ ID NO 88 **Sars-CoV1: SEQUENCE 88**
<211> LENGTH: 20
<212> TYPE: DNA **DNA**
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: S/L6/-/10542 primer

<400> SEQUENCE: 88

cctgtgcagt ttgtctgtca

<210> SEQ ID NO 89 **Sars-CoV1: SEQUENCE 89**
<211> LENGTH: 20
<212> TYPE: DNA **DNA**
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: S/L6+/10677 primer

<400> SEQUENCE: 89

ccttgtggca atgaagtaca

<210> SEQ ID NO 90 **Sars-CoV1: SEQUENCE 90**
<211> LENGTH: 20
<212> TYPE: DNA **DNA**
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: S/L6+/10106 primer

<400> SEQUENCE: 90

atgtcatttg cacagcagaa

<210> SEQ ID NO 91 **Sars-CoV1: SEQUENCE 91**
<211> LENGTH: 20
<212> TYPE: DNA **DNA**
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: S/L6+/9571 primer

<400> SEQUENCE: 91

cttcaatggt ttgccatggt

Listing of the 158 DNA and Protein sequences inserted, by Pasteur Institute people, into the Sars-CoV coronavirus, taken, in 2003, from a patient at the French hospital in Hanoi
Following up

Sars-CoV1: SEQUENCE 121

<210> SEQ ID NO 121
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: S/L11+/19021 primer

<400> SEQUENCE: 121

acgatgctca gccatgtagt

DNA

Sars-CoV1: SEQUENCE 122

<210> SEQ ID NO 122
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: SARS/L1/F3+/800 primer

<400> SEQUENCE: 122

gaggtgcagt cactcgctat

DNA

Sars-CoV1: SEQUENCE 123

<210> SEQ ID NO 123
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: SARS/L1/F4+/1391 primer

<400> SEQUENCE: 123

cagagattgg acctgagcat

DNA

Sars-CoV1: SEQUENCE 124

<210> SEQ ID NO 124
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: SARS/L1/F5+/1925 primer

<400> SEQUENCE: 124

cagcaaacca ctcaattcct

DNA

Listing of the 158 DNA and Protein sequences inserted, by Pasteur Institute people, into the Sars-CoV coronavirus, taken, in 2003, from a patient at the French hospital in Hanoi
Following up

Sars-CoV1: SEQUENCE 140
<210> SEQ ID NO 140
<211> LENGTH: 7788
<212> TYPE: DNA **DNA**
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic S gene

<400> SEQUENCE: 140

tcaatattgg ccattagcca tattattcat tggttatata gcataaatca atattggcta 60
ttggccattg catacgttgt atctatatca taatatgtac atttatattg gctcatgtcc 120
aatatgaccg ccatgttggc attgattatt gactagttat taatagtaat caattacggg 180
gtcattagtt catagcccat atatggagtt ccgcgttaca taacttacgg taaatggccc 240

Sars-CoV1: SEQUENCE 157
<210> SEQ ID NO 157
<211> LENGTH: 20
<212> TYPE: DNA **DNA**
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: PCR primer

<400> SEQUENCE: 157

ccatttcaac aatttggccg

Sars-CoV1: SEQUENCE 158
<210> SEQ ID NO 158
<211> LENGTH: 45
<212> TYPE: DNA **DNA**
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: PCR primer

<400> SEQUENCE: 158

ataggatccg cgcgctcatt atttatcgtc gtcactctta taatc

From Sars-CoV1
to
Sars-CoV2

In 2011

From Sars-CoV1 to Sars-CoV2

But Sars-CoV2 is identical, in all points, to Sars-CoV1



Institut Pasteur



Frédéric Tangy

CONTINUATION OF
Patent EP 1 694 829 B1
Patent US 012.8224 A1

Sars-CoV1



Sars-CoV2

Produced by inserting 1 DNA sequence
(29746 nucleotides) + 157 DNA and PRT
sequences into the Sars-CoV RNA genome

Patent US 8,243,718 B2



US008343718B2

(12) **United States Patent**
Van Der Werf et al.

(10) **Patent No.:** **US 8,343,718 B2**

(45) **Date of Patent:** **Jan. 1, 2013**

(54) **STRAIN OF SARS-ASSOCIATED CORONAVIRUS AND APPLICATIONS THEREOF**

(75) Inventors: **Sylvie Van Der Werf**, Gif-Sur-Yvette (FR); **Nicolas Escriou**, Paris (FR); **Bernadette Crescenzo-Chaigne**, Neuilly-Sur-Seine (FR); **Jean-Claude Manuguerra**, Paris (FR); **Frederik Kunst**, Paris (FR); **Benoît Callendret**, Nanterre (FR); **Jean-Michel Betton**, Paris (FR); **Valérie Lorin**, Montrouge (FR); **Sylvie Gerbaud**, Saint-Maur-Des-Fosses (FR); **Ana Maria Burguiere**, Clamart (FR); **Saliha Azebi**, Vitry-Sur-Seine (FR); **Pierre Charneau**, Paris (FR); **Frédéric Tangy**, Les Lilas (FR); **Chantal Combredet**, Paris (FR); **Jean-François Delagneau**, La Celle Saint Cloud (FR); **Monique Martin**, Chatenay Malabry (FR)

(73) Assignees: **Institut Pasteur**, Paris (FR); **Centre National de la Recherche Scientifique**, Paris (FR); **Universite Paris 7**, Paris (FR)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **12/754,908**

(22) Filed: **Apr. 6, 2010**

(65) **Prior Publication Data**

US 2011/0065089 A1 Mar. 17, 2011

Related U.S. Application Data

(60) Division of application No. 10/581,356, filed on Feb. 8, 2007, now Pat. No. 7,736,850, which is a continuation of application No. PCT/FR2004/003106, filed on Dec. 2, 2004.

(30) **Foreign Application Priority Data**

Dec. 2, 2003 (FR) 03 14151
 Dec. 2, 2003 (FR) 03 14152

(51) **Int. Cl.**
C12Q 1/70 (2006.01)
G01N 33/53 (2006.01)
G01N 33/542 (2006.01)
G01N 33/00 (2006.01)

(52) **U.S. Cl.** **435/5; 435/7.1; 435/7.9; 435/7.92; 435/7.94; 435/7.95**

(58) **Field of Classification Search** None
 See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2003/0008332 A1 * 1/2003 Ryan et al. 435/7.22
 2005/0100883 A1 * 5/2005 Wang et al. 435/5

OTHER PUBLICATIONS

Azcona-Olivera et al. Generation of Antibodies Reactive with Fumonisin B1, B2, and B3 by Using Cholera Toxin as the Carrier-Adjuvant. *Applied and Environmental Microbiology*, Jan. 1992, vol. 58, No. 1, pp. 169-173.*
 Li et al. The Epitope Study on the SARS-CoV Nucleocapsid Protein. *Genomics, Proteomics and Bioinformatics*, Aug. 2003, vol. 1, No. 3, pp. 198-206.*
 Wirtz et al. Comparative testing of monoclonal antibodies against *Plasmodium falciparum* sporozoites for ELISA development. *Bulletin of the World Health Organization* 1987, vol. 65, No. 1, pp. 39-45.*
 Voller et al. Enzyme immunoassays with special reference to ELISA techniques. *Journal of Clinical Pathology* 1978, vol. 31, p. 507-520.*
 Kemeny et al. Development of a semi-quantitative enzyme-linked immunosorbent assay (ELISA) for detection of human IgG subclass antibodies. *Journal of Immunologica Methods* 1987, Vol.*
 Li et al. Detection and analysis of SARS coronavirus-specific antibodies in sera from non-Sars children. *Di Yi Jun Yi Da Xue Xue Bao (Journal of the First Military Medical University)* Oct. 2003, vol. 23, No. 10, pp. 1085-1087.*
 Database EMBL, XP002294758, Database accession No. AY278489, "EMBL Sequence Version Archive", pp. 1-7, (Apr. 22, 2003).
 Database EMBL, XP002294760, Database accession No. AY290752, "EMBL Sequence Version Archive", pp. 1-2, (Jun. 10, 2003).
 Database UNIPROT, XP002294761, Database accession No. P59595, pp. 1-4, "Human Coronavirus", (Oct. 10, 2003).
 Marra, et al., "The Genome Sequence of the SARS-Associated Coronavirus", *Science, American Association for the Advancement of Science*, vol. 300, No. 5624, pp. 1399-1404, (May 30, 2003).
 Che, et al., "Rapid and Efficient Preparation of Monoclonal Antibodies Against SARS-Associated Coronavirus Nucleocapsid Protein By Immunizing Mice", *Di Yi Junyi Daxue Xuebao—Academic Journal of First Medical College of PLA, Gain Kan Bianjishi, Guangzhou, CN*, vol. 23, No. 7, pp. 640-642, (Jul. 2003).
 Wang, et al., "Assessment of Immunoreactive Synthetic Peptides from the Structural Proteins of Severe Acute Respiratory Syndrome Coronavirus", *Clinical Chemistry, American Association for Clinical Chemistry, Winston, US*, vol. 49, No. 12, pp. 1989-1996, (Nov. 13, 2003).
 Shi, et al., "Diagnosis of Severe Acute Respiratory Syndrome (SARS) by Detection of SARS Coronavirus Nucleocapsid Antibodies in an Antigen-Capturing Enzyme-Linked Immunosorbent Assay", *Journal of Clinical Microbiology, Washington, DC, US*, vol. 41, No. 12, pp. 5781-5782, (Dec. 2003). Liu, et al., "The C-Terminal Portion of the Nucleocapsid Protein Demonstrates SARS-CoV Antigenicity", *Genomics, Proteomics and Bioinformatics*, vol. 1, No. 3, pp. 193-197, (Aug. 2003).
 Poon, et al., "Rapid Diagnosis of a Coronavirus Associated with Severe Acute Respiratory Syndrome (SARS)", *Clinical Chemistry, American Association for Clinical Chemistry, Winston, US*, vol. 49, No. 6, Pt. 1, pp. 953-955, (Jun. 2003).

* cited by examiner

Primary Examiner — Louise Humphrey

(74) *Attorney, Agent, or Firm* — Finnegan, Henderson, Farabow, Garrett & Dunner L.L.P.

(57) **ABSTRACT**

The invention relates to a novel strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from a sample collected in Hanoi (Vietnam), reference number 031589, nucleic acid molecules originating from the genome of same, proteins and peptides coded by said nucleic acid molecules and, more specifically, protein N and the applications thereof, for example, as diagnostic reagents and/or as a vaccine.

8 Claims, 116 Drawing Sheets

From Sars-CoV2
to
Covid-19

From Sars-CoV2 to Covid-19

From 2011 to 2015



Pierre Charneau



Frédéric Tangy



**Insertion of 4 fragments of HIV1,
corresponding to the short amino acid
segments of the gp 120 and of the HIV1 Gag,
into the Sars-CoV2 genome**

Sars-CoV2

identical to Sars-CoV1



Covid-19

**Insertion carried out at the Institut
Pasteur between 2011 and 2015**

Manufacture of virus responsible for COVID 19 disease

Between 2011 and 2015, French scientists from the Institut Pasteur manufactured the virus responsible for the **COVID 19 disease**, which they called **Covid-19**, by inserting 4 RNA sequences from HIV1, the AIDS virus, into the Sars-CoV2 genome.

It was Dr Pierre Charneau, Head of the Molecular Virology and Vaccinology Unit at the Institut Pasteur, and specialist in the integration of HIV into the DNA of the human genome, who was responsible for this genetic manipulation.

Doctor Pierre Charneau made Sars nCoV-19 from Sars-CoV2



Doctor Pierre Charneau

Head of the Molecular Virology and Vaccinology (VMV) Unit at the Institut Pasteur Scientific Director and Head of the Joint Laboratory between Institut Pasteur and **Theravectys**

Pierre Charneau is a recognized specialist in HIV, the AIDS virus, lentiviral gene transfer vectors and their medical applications. He holds a research doctorate in molecular and cellular biology.

In 1995, he did his doctoral thesis in Luc Montagnier's viral oncology laboratory at the Institut Pasteur on: "Reverse transcription, nuclear importation and independent integration of the mitosis of the HIV genome". Dr. Pierre Charneau, specialist in the integration of HIV into the DNA of the human genome, was responsible for inserting the RNA sequences of the AIDS virus into the Sars-CoV2 genome, between 2011 and 2015; which gave birth to the artificial coronavirus nCoV-19, responsible for the COVID-19 epidemic, triggered by the Institut Pasteur in 2019. In the ChAdOx1 nCoV-19 vaccine, the nCoV-19 coronavirus is carried by the vector adenovirus ChAdOx1

- **Pierre Charneau is inventor in the 3 patents protecting artificial virus Sars-CoV1 from Institut Pasteur**

- **2003** : inventor together with Frédéric Tangy, in patents EP 1694829 B1 and US 012.8224 A1

- **2011**: inventor together with Frédéric Tangy, in patent US 8,343,718 B2

- **Publications by Pierre Charneau concerning the nuclear importation of HIV into human cells**

1- Véronique Zennou, Caroline Petit, Denise Guetard, Ulf Nerhbass, Luc Montagnier, and Pierre Charneau. *VII-1 Genome Nuclear Import Is Mediated by a Central DNA Flap*. Cell, Vol. 101, 173–185, April 14, 2000

2- Aude Sirven, Françoise Pflumio, Véronique Zennou, Monique Titeux, William Vainchenker, Laure Coulombel, Anne Dubart-Kupperschmitt, Pierre Charneau. *The human immunodeficiency virus type-1 central DNA flap is a crucial determinant for lentiviral vector nuclear import and gene transduction of human hematopoietic stem cells*. BLOOD, 15 DECEMBER 2000, VOLUME 96, NUMBER 13

Characteristics of HIV1, the AIDS virus

To read this article, see DOCUMENT 14

Transformation of Sars-CoV-2 into Covid-19

The **Sars-CoV-2** coronavirus, described in **US Patent 8,343,718 B2** , is an RNA virus into the genome of which **DNA sequences**, **but not RNA sequences**, have been inserted.

Recently, and simultaneously, **Professor Luc Montagnier** and a **group of Indian scientists** have **analyzed** and **decrypted** the **complete genome of the Covid-19** coronavirus responsible for the pandemic.

They found in the Covid-19 genome:

- **sequences of HIV**, the **AIDS virus** (4 fragments of HIV1 RNA which correspond to short segments of amino acids found in the gp120 and the Gag of HIV1);
- and **DNA sequences** from the **malaria** germ.

These results have been published and confirmed by **Professor Peter Chumakov**, a well-known Russian microbiologist, and Japanese **Professor Tasuku Honjo**, 2018 Nobel Prize laureate in medicine. **Since there was no RNA sequence in Sars-CoV-2** described in **US Patent 8,343,718 B2**, this analysis proves that **Covid-19 is the result of genetic manipulation of Sars-CoV-2 by French scientists from the Institut Pasteur.**

Interview with professor Luc Montagnier by doctor Jean-François Lemoine
Health site: Medical Frequency and Why Doctor
(Thursday April 16, 2020)

To read this interview, see [DOCUMENT 1](#)

**The Covid-19 virus is not Sars-CoV2,
but Sars nCoV-19, manufactured before 2015**

The Institut Pasteur claimed that the virus responsible of the **COVID-19 disease**, which they called **Covid-19**, was **Sars-CoV-2**. And that **they discovered this natural virus in December 2019**.

This is totally wrong!

Evidence of the manufacture of the artificial virus, responsible for the COVID-19 disease, by the Institut Pasteur, before 2015

In early October 2020, a group of German doctors discovered the existence of a patent for the invention of COVID-19 testing, US patent US 2015/622,407 P, filed by Richard Rothschild, with a date of priority as of October 13, 2015.

Patent title:

SYSTEM AND METHOD FOR TESTING FOR COVID-19

Related U.S. Application Data:

(63) Continuation - in - part of application No. 16 / 704,844, filed on Dec. 5, 2019, which is a continuation of application No. 16 / 273,141, filed on Feb. 11, 2019, now Pat. No. 10,522,188, which is a continuation of application No. 15 / 495,485, filed on Apr. 24, 2017, now Pat. No. 10,242,713, which is a continuation of application No. 15 / 293,211, filed on Oct. 13, 2016, now abandoned.

(60) Provisional application No. 62 / 240,783, filed on Oct. 13, 2015.

The first patent was therefore filed on October 13, 2015

ABSTRACT

A method is provided for acquiring and transmitting biometric data (e.g., vital signs) of a user, where the data is analyzed to determine whether the user is suffering from a viral infection, such as COVID – 19.

COVID 19 tests are therefore used to detect COVID-19 viral infection in patients



RESULTAATLIJST

Selecteer alles (0/1) Compact  Exporteer (CSV | XLS)  Download eerste pagina's

1 treffer in databank Worldwide voor zoekvraag:
covid in de titel AND Richard Rothschild als aanvrager

1. System and Method for Testing for COVID -19

★ **Uitvinder:**
ROTHSCHILD
RICHARD A [GB]

Aanvrager:
ROTHSCHILD
RICHARD A [GB]

CPC:
[G06K2009/00939](#)
[G06K9/00892](#)
[G11B27/031](#)
(+5)

IPC:
G06K9/00
G11B27/031
G11B27/10
(+3)

Prioriteitsdatum:
2015-10-13



US 20200279585A1

(19) **United States**

(12) **Patent Application Publication**
Rothschild

(10) **Pub. No.: US 2020/0279585 A1**
(43) **Pub. Date: Sep. 3, 2020**

(54) **SYSTEM AND METHOD FOR TESTING FOR COVID-19**

(71) Applicant: **Richard A. Rothschild**, London (GB)

(72) Inventor: **Richard A. Rothschild**, London (GB)

(21) Appl. No.: **16/876,114**

(22) Filed: **May 17, 2020**

G06K 9/00 (2006.01)
H04N 5/76 (2006.01)
H04N 9/82 (2006.01)
G16H 40/63 (2006.01)

(52) **U.S. CL.**
CPC **G11B 27/10** (2013.01); **G11B 27/031** (2013.01); **G06K 9/00892** (2013.01); **G06K 2009/00939** (2013.01); **H04N 9/8205** (2013.01); **G11B 27/102** (2013.01); **G16H 40/63** (2018.01); **H04N 5/76** (2013.01)

Related U.S. Application Data


(63) Continuation-in-part of application No. 16/704,844, filed on Dec. 5, 2019, which is a continuation of application No. 16/273,141, filed on Feb. 11, 2019, now Pat. No. 10,522,188, which is a continuation of application No. 15/495,485, filed on Apr. 24, 2017, now Pat. No. 10,242,713, which is a continuation of application No. 15/293,211, filed on Oct. 13, 2016, now abandoned.

(60) **Provisional application No. 62/240,783, filed on Oct. 13, 2015.**

Publication Classification

(51) **Int. Cl.**
G11B 27/10 (2006.01)
G11B 27/031 (2006.01)

(57) **ABSTRACT**
A method is provided for acquiring and transmitting biometric data (e.g., vital signs) of a user, where the data is analyzed to determine whether the user is suffering from a viral infection, such as COVID-19. The method includes using a pulse oximeter to acquire at least pulse and blood oxygen saturation percentage, which is transmitted wirelessly to a smartphone. To ensure that the data is accurate, an accelerometer within the smartphone is used to measure movement of the smartphone and/or the user. Once accurate data is acquired, it is uploaded to the cloud (or host), where the data is used (alone or together with other vital signs) to determine whether the user is suffering from (or likely to suffer from) a viral infection, such as COVID-19. Depending on the specific requirements, the data, changes thereto, and/or the determination can be used to alert medical staff and take corresponding actions.



Le brevet US 62240783 P a été déposé le 13 octobre 2015 par Richard A ROTHSCHILD

Dossier mondial [↗](#)

Demandeurs ROTHSCHILD RICHARD A [GB] +

Inventeurs ROTHSCHILD RICHARD A [GB] +

Classifications

CIB **G06K9/00; G11B27/031; G11B27/10; G16H40/63; H04N5/76; H04N9/82;**

CPC **G06K9/00892 (US); G11B27/031 (US); G11B27/10 (US); G11B27/102 (US); G16H40/63 (EP,US); G16H40/67 (EP); G16H50/20 (EP); H04N5/76 (EP,US); H04N9/8205 (EP,US); G06K2009/00939 (US);**

Priorités **US201562240783P-2015-10-13;** US201615293211A-2016-10-13; US201715495485A-2017-04-24; US201916273141A-2019-02-11; US201916704844A-2019-12-05; US202016876114A-2020-05-17

Demande US202016876114A-2020-05-17

Publication US2020279585A1-2020-09-03

Publié en tant que US2020279585A1

What the COVID-19 Tests Patent and the 2017 COVID-19 Tests Sales tell Us

The Institut Pasteur, WHO, all Western health agencies, governments of Western countries, and pharmaceutical companies, had therefore programmed the COVID 19 epidemic, before 2015, when the COVID-19 test patent was filed.

Moreover, to add to the horror and the lies, we come to learn that the tests had been sold in 2017 to a large number of countries for sums of over \$ 10 billion.

Hold up à 1h : 52 : 01

The screenshot shows the WITS website interface. At the top, there is a navigation bar with links for Trade Stats, Tariffs, Non-Tariff Measures, API, Analytical database, Tools, and Bulk Download. Below this is a secondary navigation bar with Home, About WITS, Reference, Training, and Support Links. The main content area features a yellow header for the current report: "COVID-19 Diagnostic Test instruments and apparatus (902780) exports by country in 2017". Below the header, there is a section for "Additional Product information" and a "Category" label. A paragraph of text lists the top exporters in 2017. Below this is another yellow header for "COVID-19 Diagnostic Test instruments and apparatus imports by country in 2017". At the bottom, a table displays the export data for 2017.

COVID-19 Diagnostic Test instruments and apparatus (902780) exports by country in 2017

Additional Product information: Instruments used in clinical laboratories for In Vitro Diagnosis. Colorimetric end tidal CO2 detector, sizes compatible with child and adult endotracheal tube. Single use.

Category: COVID-19 Test kits/ Instruments, apparatus used in Diagnostic Testing

In 2017, Top exporters of COVID-19 Diagnostic Test instruments and apparatus are European Union (\$2,646,826.94K), United States (\$2,311,980.25K , 2,628,910 Item), Germany (\$2,152,116.86K), Japan (\$1,176,454.27K), China (\$647,604.66K).

COVID-19 Diagnostic Test instruments and apparatus imports by country in 2017

Reporter	TradeFlow	ProductCode	Product Description	Year	Partner	Trade Value 1000USD	Quantity	Quantity Unit
European Union	Export	902780	COVID-19 Diagnostic Test instruments and apparatus	2017	World	2,646,826.94		
United States	Export	902780	COVID-19 Diagnostic Test instruments and apparatus	2017	World	2,311,980.25	2,628,910	Item
Germany	Export	902780	COVID-19 Diagnostic Test instruments and apparatus	2017	World	2,152,116.86		
Japan	Export	902780	COVID-19 Diagnostic Test instruments and apparatus	2017	World	1,176,454.27		
China	Export	902780	COVID-19 Diagnostic Test instruments and apparatus	2017	World	647,604.66		
Hong Kong, China	Export	902780	COVID-19 Diagnostic Test instruments and apparatus	2017	World	608,274.17	6,962,400	Item

The virus responsible for the COVID-19 disease is not a Chinese virus that escaped from the P4 laboratory in Wuhan

The incredible discovery of the **COVID-19 test patent**, provides us with an answer on the **non-involvement of China in the origin of the epidemic**, which we have tried to attribute to an accidental leak of the Covid-19 virus from the Wuhan P4 laboratory, without having any proof.

In February 2017, a delegation from the French government and the Institut Pasteur traveled to Wuhan to inaugurate the new P4 laboratory in Wuhan as part of a collaboration between France and China. On the following photo we recognize **Elizabeth Guigou**, **Marisol Touraine**, then Minister of Health, **Yves Lévy**, husband of Agnès Buzyn, who was director of INSERM, at that time, **Bernard Cazeneuve**, Minister of the Interior, and a **director of the Institut Pasteur**.

This visit took place on February 23, 2017, as shown in the photo.

There was a lot of hype in the press to get everyone to believe in a real scientific collaboration between Chinese scientists at the P4 laboratory in Wuhan and the Institut Pasteur. In fact this collaboration never took place.

In February 2017, these people knew that the virus responsible for the COVID-19 disease was already manufactured by the Institut Pasteur, before 2015, and this visit had only one goal: to blame the Chinese on the origin of this virus and the false pandemic.



To read the full article see [DOCUMENT 2](#)

VIRAL IMMUNOLOGY, Volume 18, Number 2,
2005 © Mary Ann Liebert, Inc.
Pp. 317-326

Review

Live Attenuated Measles Vaccine as a Potential Multivalent Pediatric Vaccination Vector

FRÉDÉRIC TANGY¹ and HUSSEIN Y. NAIM²

(1- Unité des Virus Lents, CNRS URA 1930, Institut Pasteur, Paris, France. 2- Berna Biotech LTD, Rehhagstrasse 79, 3018 Bern, Switzerland)

ABSTRACT

Live attenuated RNA viruses make highly efficient vaccines. Among them is the live attenuated measles virus (MV) vaccine that has been given to a very large number of children and has been shown to be highly efficacious and safe. MV vaccine induces a life-long immunity after a single injection or two low-dose injections. It is easily produced on a large scale in most countries and can be distributed at low cost. Reversion to pathogenicity has never been observed with this vaccine. For all of these characteristics, developing of MV vaccine vector as a multivalent vaccine to immunize children against both measles and other infectious agents such as human immunodeficiency virus (HIV), flaviviruses, or malaria might be very promising for worldwide use. As MV vaccine is inexpensive to produce, the generation of recombinant vaccines may remain affordable and attractive for the developing world. In this article, we describe the development of MV vector and present some recent data showing the capacity of recombinant MV vaccine to express various proteins from HIV and West Nile virus. In addition, the ability of recombinant MV to induce specific immune responses against these different pathogens are presented and discussed.

Interview with Doctor Frédéric Tangy
Paris-Match article from April 9-15, 2020

To read this interview, see [DOCUMENT 3 and 4](#)

Extract from Document 4

Elaboration of Covid-19 vaccine according to Dr Frédéric Tangy

The complete and detailed «recipe» for one Covid 19 vaccine, was given to us by Dr Frédéric Tangy, head of Vaccine Innovation at the Institut Pasteur in Paris, in an interview with the newspaper Paris-Match, in the 9-15 edition April 2020 (see Document 4).

Thus, as explained perfectly to us by Dr. Frédéric Tangy - who is decidedly very talkative - the spike glycoprotein of Covid-19, which contains the 4 RNA sequences of HIV -which is clear from the group's analysis of Indian researchers, but was hidden (like malaria genome) by researchers at the Institut Pasteur - is intended, he said, to induce immunity in the vaccine, serving as an antigen after insertion into the genome of the attenuated measles virus (who remember it is an RNA). But, obviously, it does not tell us that the viral nucleic acids inserted into the genome of the attenuated measles virus are those of HIV. And, since it is not in the Sars-CoV-2 coronavirus genome, one wonders where it came from.

It should be noted that Dr. Frédéric Tangy gave this interview a few days before that of Pr Luc Montagnier.

From Covid-19
to
Covid-19 Vaccines

From Covid-19 to Covid-19 Vaccines

Covid-19

Insertion of Covid-19 genome into the genome of a viral vector

(ChAdOx1 chimpanzee DNA adenovirus)

See Publication DOCUMENT 23 USB

Jenner Institute



Adrian Hill

Covid-19 vaccines

ChAdOx1 nCoV-19 (GSK, Sanofi)


Insertion of tracing nanoparticles in the vaccine vial to be injected into the human body together with the vaccine

US Patent WO 2020/060606 A1
PCT/US20 19/038084 Microsoft

Final vaccine

NANOPARTICLES OF Covid-19 VACCINES

CRYPTOCURRENCY SYSTEM USING BODY ACTIVITY DATA



Bill Gates

NANOPARTICLES of Covid-19 VACCINES

Satellites for 5G

100

Task server



110

Cryptocurrency System

150

Communication Network
5G relays

120

Nanoparticles

injected
together with vaccine

Vaccinated people



145

Sensor
Nanoparticles

140

User Device
Mobile phones

130



Bill Gates

Nanoparticles and the permanent control of vaccinated people

The **nanoparticles** described in the Microsoft patent (US Patent WO 2020/060606 A1) are **sensors** which **must be diffused in the body of the vaccinated person, in order to be able to detect it**

Introduced into the vaccine vial, **they are injected into the body, together with the vaccine**, at the time of vaccination

Once they are in the body, they cannot be gotten rid of, unlike a subcutaneous digital tracing microchip. From this moment, **the vaccinated people will be detectable by any mobile phone located nearby.**

Mobile phones are connected to the internet by 5G

5G relays allow this **communication** through **satellites 5G.**

The vaccinated people will have lost definitely all freedom in their existence

Are 160 Covid-19 vaccines really in development?

**According to information provided by the NIH and WHO,
160 vaccines against Covid-19 are under development**

**The list of the 160 candidates for Covid-19 vaccines in
development was compiled by the NIH**

**Of these 160 candidates
only 21 clinical study protocols
have been written by the NIH**

NIH: National Institute of Health (whose director general is Anthony Fauci)

WHO: World Health Organization (whose director general is Tedros Adhanom Ghebreyesus)

List of candidates for Covid-19 vaccines in development

DRAFT landscape of COVID-19 candidate vaccines – 7 July 2020

21 candidate vaccines in clinical evaluation

Platform	Type of candidate vaccine	Developer	Coronavirus target	Current stage of clinical evaluation/regulatory status- Coronavirus candidate	Same platform for non-Coronavirus candidates
Inactivated	Inactivated + alum	Sinovac	SARS-CoV2	Phase 3 NCT04456595 Phase 1/2 NCT04383574 NCT04352608	SARS
Non-Replicating Viral Vector	ChAdOx1-S	University of Oxford/AstraZeneca	SARS-CoV2	Phase 3 ISRCTN89951424 Phase 2b/3 2020-001228-32 Phase 1/2 PACTR202006922165132 2020-001072-15	MERS, influenza, TB, Chikungunya, Zika, MenB, plague
Non-Replicating Viral Vector	Adenovirus Type 5 Vector	CanSino Biological Inc./Beijing Institute of Biotechnology	SARS-CoV2	Phase 2 ChiCTR2000031781 Phase 1 ChiCTR2000030906	Ebola
RNA	LNP-encapsulated mRNA	Moderna/NIAID	SARS-CoV2	Phase 2 NCT04405076 Phase 1 NCT04283461	multiple candidates
DNA	DNA plasmid vaccine with electroporation	Inovio Pharmaceuticals/ International Vaccine Institute	SARS-CoV2	Phase 1/2 NCT04447781 NCT04336410	multiple candidates
DNA	DNA plasmid vaccine	Cadila Healthcare Limited	SARS-CoV2	Phase 1/2 CTRI/2020/07/026352 (not yet recruiting)	
Inactivated	Inactivated	Wuhan Institute of Biological Products/Sinopharm	SARS-CoV2	Phase 1/2 ChiCTR2000031809	
Inactivated	Inactivated	Beijing Institute of Biological Products/Sinopharm	SARS-CoV2	Phase 1/2 ChiCTR2000032459	
Protein Subunit	Full length recombinant SARS CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M	Novavax	SARS-CoV2	Phase 1/2 NCT04368988	RSV; CCHF, HPV, VZV, EBOV
RNA	3 LNP-mRNAs	BioNTech/Fosun Pharma/Pfizer	SARS-CoV2	Phase 1/2 2020-001038-36 NCT04368728	
DNA	DNA Vaccine (GX-19)	Genexine Consortium	SARS-CoV2	Phase 1 NCT04445389	
DNA	DNA plasmid vaccine + Adjuvant	Osaka University/ AnGes/ Takara Bio	SARS-CoV2	Phase 1 JapicCTI-205328	

DISCLAIMER:

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.

FOLLOWING

Inactivated	Inactivated	Institute of Medical Biology , Chinese Academy of Medical Sciences	SARS-CoV2	Phase 1 NCT04412538	
Non-Replicating Viral Vector	Adeno-based	Gamaleya Research Institute	SARS-CoV2	Phase 1 NCT04436471 NCT04437875	
Protein Subunit	Native like Trimeric subunit Spike Protein vaccine	Clover Biopharmaceuticals Inc./GSK/Dynavax	SARS-CoV2	Phase 1 NCT04405908	HIV, REV Influenza
Protein Subunit	Adjuvanted recombinant protein (RBD-Dimer)	Anhui Zhifei Longcom Biopharmaceutical/ Institute of Microbiology, Chinese Academy of Sciences	SARS-CoV2	Phase 1 NCT04445194	MERS
Protein Subunit	Recombinant spike protein with Advax™ adjuvant	Vaxine Pty Ltd/Medytox	SARS-CoV2	Phase 1 NCT04453852	
RNA	LNP-nCoVsaRNA	Imperial College London	SARS-CoV2	Phase 1 ISRCTN17072692	EBOV; LASV, MARV, Inf (H7N9), RABV
RNA	mRNA	Curevac	SARS-CoV2	Phase 1 NCT04449276	RABV, LASV, YFV; MERS, InfA, ZIKV, DENV, NIPV
RNA	mRNA	People's Liberation Army (PLA) Academy of Military Sciences/Walvax Biotech.	SARS-CoV2	Phase 1 ChiCTR2000034112	
VLP	Plant-derived VLP	Medicago Inc./ Université Laval	SARS-CoV2	Phase 1 NCT04450004 (not yet recruiting)	Flu, Rotavirus, Norovirus, West Nile virus, Cancer

FOLLOWING

139 candidate vaccines in preclinical evaluation

Platform	Type of candidate vaccine	Developer	Coronavirus target	Current stage of clinical evaluation/regulatory status- Coronavirus candidate	Same platform for non-Coronavirus candidates
DNA	DNA vaccine	Ege University	SARS-CoV2	Pre-Clinical	
DNA	DNA plasmid vaccine RBD&N	Scancell/University of Nottingham/ Nottingham Trent University	SARS-CoV2	Pre-Clinical	
DNA	DNA plasmid vaccine S,S1,S2,RBD &N	National Research Centre, Egypt	SARS-CoV2	Pre-Clinical	
DNA	DNA with electroporation	Karolinska Institute / Cobra Biologics (OPENCORONA Project)	SARS-CoV2	Pre-Clinical	
DNA	DNA with electroporation	Chula Vaccine Research Center	SARS-CoV2	Pre-Clinical	
DNA	DNA	Takis/Applied DNA Sciences/Evvivax	SARS-CoV2	Pre-Clinical	
DNA	Plasmid DNA, Needle-Free Delivery	Immunomic Therapeutics, Inc./EpiVax, Inc./PharmaJet	SARS-CoV2	Pre-Clinical	SARS
DNA	DNA vaccine	BioNet Asia	SARS-CoV2	Pre-Clinical	
DNA	msDNA vaccine	Mediphage Bioceuticals/University of Waterloo	SARS-CoV2	Pre-Clinical	
DNA	DNA vaccine	Entos Pharmaceuticals	SARS-CoV2	Pre-Clinical	
DNA	bacTRL-Spike	Symvivo	SARS-CoV2	Pre-Clinical	
Inactivated	Inactivated + alum	KM Biologics	SARS-CoV2	Pre-Clinical	JE, Zika
Inactivated	Inactivated	Selcuk University	SARS-CoV2	Pre-Clinical	
Inactivated	Inactivated whole virus	National Research Centre, Egypt	SARS-CoV2	Pre-Clinical	
Inactivated	Inactivated	Beijing Minhai Biotechnology Co., Ltd.	SARS-CoV2	Pre-Clinical	

DISCLAIMER:

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.

FOLLOWING

Inactivated	TBD	Osaka University/ BIKEN/ NIBIOHN	SARS-CoV2	Pre-Clinical	
Inactivated	Inactivated + CpG 1018	Sinovac/Dynavax	SARS-CoV2	Pre-Clinical	
Inactivated	Inactivated + CpG 1018	Valneva/Dynavax	SARS-CoV2	Pre-Clinical	
Inactivated	Inactivated	Research Institute for Biological Safety Problems, Rep of Kazakhstan	SARS-CoV2	Pre-Clinical	
Live Attenuated Virus	Codon deoptimized live attenuated vaccines	Mehmet Ali Aydinlar University / Acibadem Labmed Health Services A.S.	SARS-CoV2	Pre-Clinical	
Live Attenuated Virus	Codon deoptimized live attenuated vaccines	Codagenix/Serum Institute of India	SARS-CoV2	Pre-Clinical	HAV, InfA, ZIKV, FMD, SIV, RSV, DENV
Live Attenuated Virus	Codon deoptimized live attenuated vaccines	Indian Immunologicals Ltd/Griffith University	SARS-CoV2	Pre-Clinical	
Non-Replicating Viral Vector	Sendai virus vector	ID Pharma	SARS-CoV2	Pre-Clinical	
Non-Replicating Viral Vector	Adenovirus-based	Ankara University	SARS-CoV2	Pre-Clinical	
Non-Replicating Viral Vector	Adeno-associated virus vector (AAVCOVID)	Massachusetts Eye and Ear/Massachusetts General Hospital/AveXis	SARS-CoV2	Pre-Clinical	
Non-Replicating Viral Vector	MVA encoded VLP	GeoVax/BravoVax	SARS-CoV2	Pre-Clinical	LASV, EBOV, MARV, HIV
Non-Replicating Viral Vector	Ad26	Janssen Pharmaceutical Companies	SARS-CoV2	Pre-Clinical	Ebola, HIV, RSV
Non-Replicating Viral Vector	Replication defective Simian Adenovirus (GRAd) encoding SARS-CoV-2 S	ReiThera/LEUKOCARE/Univercells	SARS-CoV2	Pre-Clinical	
Non-replicating viral vector	MVA-S encoded	DZIF – German Center for Infection Research/IDT Biologika GmbH	SARS-CoV2	Pre-clinical	Many
Non-replicating viral vector	MVA-S	IDIBAPS-Hospital Clinic, Spain	SARS-CoV2	Pre-clinical	
Non-Replicating Viral Vector	adenovirus-based NasoVAX expressing SARS2-CoV spike protein	Altimune	SARS-CoV2	Pre-Clinical	influenza
Non-Replicating Viral Vector	[E1-, E2b-, E3-] hAd5-COVID19-Spike/Nucleocapsid	ImmunityBio, Inc. & NantKwest, Inc.	SARS-CoV2	Pre-Clinical	flu, Chik, Zika, EBOV, LASV, HIV/SIV, Cancer
Non-Replicating Viral Vector	Ad5 S (GREVAX™ platform)	Greffex	SARS-CoV2	Pre-Clinical	MERS
Non-Replicating Viral Vector	Oral Ad5 S	Stabilitech Biopharma Ltd	SARS-CoV2	Pre-Clinical	Zika, VZV, HSV-2 and Norovirus
Non-Replicating Viral Vector	adenovirus-based + HLA-matched peptides	Valo Therapeutics Ltd	Pan-Corona	Pre-Clinical	
Non-Replicating Viral Vector	Oral Vaccine platform	Vaxart	SARS-CoV2	Pre-Clinical	InfA, CHIKV, LASV, NORV; EBOV, RVF, HBV, VEE
Non-Replicating Viral Vector	MVA expressing structural proteins	Centro Nacional Biotecnología (CNB-CSIC), Spain	SARS-CoV2	Pre-Clinical	Multiple candidates
Non-Replicating Viral Vector	Dendritic cell-based vaccine	University of Manitoba	SARS-CoV2	Pre-Clinical	

DISCLAIMER:

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.

FOLLOWING

Non-Replicating Viral Vector	parainfluenza virus 5 (PIV5)-based vaccine expressing the spike protein	University of Georgia/University of Iowa	SARS-CoV2	Pre-Clinical	MERS
Non-Replicating Viral Vector	Recombinant deactivated rabies virus containing S1	Bharat Biotech/Thomas Jefferson University	SARS-CoV2	Pre-Clinical	HeV, NiV, EBOV, LASSA, CCHFV, MERS
Non-Replicating Viral Vector	Influenza A H1N1 vector	National Research Centre, Egypt	SARS-CoV2	Pre-Clinical	
Non-Replicating Viral Vector	Inactivated Flu-based SARS-CoV2 vaccine + Adjuvant	National Center for Genetic Engineering and Biotechnology (BIOTEC) /GPO, Thailand	SARS-CoV2	Pre-Clinical	
Protein Subunit	Recombinant S protein	Izmir Biomedicine and Genome Center	SARS-CoV2	Pre-Clinical	
Protein Subunit	Peptide + novel adjuvant	Bogazici University	SARS-CoV2	Pre-Clinical	
Protein Subunit	S subunit intranasal liposomal formulation with GLA/3M052 adjs.	University of Virginia	SARS-CoV2	Pre-Clinical	
Protein Subunit	Subunit	Helix Biogen Consult, Ogbomoso & Trinity Immono-efficient Laboratory, Ogbomoso, Oyo State, Nigeria.	SARS-CoV2	Pre-Clinical	
Protein Subunit	Protein Subunit S,N,M&S1 protein	National Research Centre, Egypt	SARS-CoV2	Pre-Clinical	
Protein Subunit	Protein Subunit	University of San Martin and CONICET, Argentina	SARS-CoV2	Pre-Clinical	
Protein Subunit	RBD protein fused with Fc of IgG + Adj.	Chulalongkorn University/GPO, Thailand	SARS-CoV2	Pre-Clinical	
Protein Subunit	Capsid-like Particle	AdaptVac (PREVENT-nCoV consortium)	SARS-CoV2	Pre-Clinical	
Protein Subunit	Drosophila S2 insect cell expression system VLPs	ExpreS2ion	SARS-CoV2	Pre-Clinical	
Protein Subunit	Peptide antigens formulated in LNP	IMV Inc	SARS-CoV2	Pre-Clinical	
Protein Subunit	S protein	WRAIR/USAMRIID	SARS-CoV2	Pre-Clinical	
Protein Subunit	S protein +Adjuvant	National Institute of Infectious Disease, Japan/Shionogi/UMN Pharma	SARS-CoV2	Pre-Clinical	Influenza
Protein Subunit	VLP-recombinant protein + Adjuvant	Osaka University/ BIKEN/ National Institutes of Biomedical Innovation, Japan	SARS-CoV2	Pre-Clinical	
Protein Subunit	microneedle arrays S1 subunit	Univ. of Pittsburgh	SARS-CoV2	Pre-Clinical	MERS
Protein Subunit	Peptide	Vaxil Bio	SARS-CoV2	Pre-Clinical	
Protein Subunit	Adjuvanted protein subunit (RBD)	Biological E Ltd	SARS-CoV2	Pre-Clinical	
Protein Subunit	Peptide	Flow Pharma Inc	SARS-CoV2	Pre-Clinical	Ebola, Marburg, HIV, Zika, Influenza, HPV therapeutic vaccine, BreastCA vaccine
Protein Subunit	S protein	AJ Vaccines	SARS-CoV2	Pre-Clinical	
Protein Subunit	li-Key peptide	Generex/EpiVax	SARS-CoV2	Pre-Clinical	Influenza, HIV, SARS-CoV
Protein Subunit	S protein	EpiVax/Univ. of Georgia	SARS-CoV2	Pre-Clinical	H7N9
Protein Subunit	Protein Subunit EPV-CoV-19	EpiVax	SARS-CoV2	Pre-Clinical	
Protein Subunit	S protein (baculovirus production)	Sanofi Pasteur/GSK	SARS-CoV2	Pre-Clinical	Influenza, SARS-CoV

DISCLAIMER:

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.

FOLLOWING

Protein Subunit	gp-96 backbone	Heat Biologics/Univ. Of Miami	SARS-CoV2	Pre-Clinical	NSCLC, HIV, malaria, Zika
Protein Subunit	Molecular clamp stabilized Spike protein	University of Queensland/GSK/Dynavax	SARS-CoV2	Pre-Clinical	Nipah, influenza, Ebola, Lassa
Protein Subunit	Peptide vaccine	FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo	SARS-CoV2	Pre-Clinical	Ebola
Protein Subunit	Subunit vaccine	FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo	SARS-CoV2	Pre-Clinical	
Protein Subunit	S1 or RBD protein	Baylor College of Medicine	SARS-CoV2	Pre-Clinical	SARS
Protein Subunit	Subunit protein, plant produced	iBio/CC-Pharming	SARS-CoV2	Pre-Clinical	
Protein Subunit	Recombinant protein, nanoparticles (based on S-protein and other epitopes)	Saint-Petersburg scientific research institute of vaccines and serums	SARS-CoV2	Pre-Clinical	
Protein Subunit	COVID-19 XWG-03 truncated S (spike) proteins	Innovax/Xiamen Univ./GSK	SARS-CoV2	Pre-Clinical	HPV
Protein Subunit	Adjuvanted microsphere peptide	VIDO-InterVac, University of Saskatchewan	SARS-CoV2	Pre-Clinical	
Protein Subunit	Synthetic Long Peptide Vaccine candidate for S and M proteins	OncoGen	SARS-CoV2	Pre-Clinical	
Protein Subunit	Oral E. coli-based protein expression system of S and N proteins	MIGAL Galilee Research Institute	SARS-CoV2	Pre-Clinical	
Protein Subunit	Nanoparticle vaccine	LakePharma, Inc.	SARS-CoV2	Pre-Clinical	
Protein Subunit	Plant-based subunit (RBD-Fc + Adjuvant)	Baiya Phytopharm/ Chula Vaccine Research Center	SARS-CoV2	Pre-Clinical	
Protein Subunit	OMV-based vaccine	Quadram Institute Biosciences	SARS-CoV2	Pre-Clinical	Flu A, plague
Protein Subunit	OMV-based vaccine	BiOMViS Srl/Univ. of Trento	SARS-CoV2	Pre-Clinical	
Protein subunit	structurally modified spherical particles of the tobacco mosaic virus (TMV)	Lomonosov Moscow State University	SARS-CoV2	Pre-Clinical	rubella, rotavirus
Protein Subunit	Spike-based	University of Alberta	SARS-CoV2	Pre-Clinical	Hepatitis C
Protein Subunit	Recombinant S1-Fc fusion protein	AnyGo Technology	SARS-CoV2	Pre-Clinical	
Protein Subunit	Recombinant protein	Yisheng Biopharma	SARS-CoV2	Pre-Clinical	
Protein Subunit	Recombinant S protein in IC-BEVS	Vabiotech	SARS-CoV2	Pre-Clinical	
Protein Subunit	Orally delivered, heat stable subunit	Applied Biotechnology Institute, Inc.	SARS-CoV2	Pre-Clinical	
Protein Subunit	S-2P protein + CpG 1018	Medigen Vaccine Biologics Corporation/NIAID/Dynavax	SARS-CoV2	Pre-Clinical	
Protein Subunit	Peptides derived from Spike protein	Axon Neuroscience SE	SARS-CoV2	Pre-Clinical	
Protein Subunit	Protein Subunit	MOGAM Institute for Biomedical Research, GC Pharma	SARS-CoV2	Pre-Clinical	
Protein Subunit	RBD-based	Neovii/Tel Aviv University	SARS-CoV2	Pre-Clinical	
Protein Subunit	RBD-based	Kentucky Bioprocessing, Inc	SARS-CoV2	Pre-Clinical	
Protein Subunit	Outer Membrane Vesicle (OMV)-subunit	Intravacc/Epivax	SARS-CoV2	Pre-Clinical	
Protein Subunit	Outer Membrane Vesicle(OMV)-peptide	Intravacc/Epivax	SARS-CoV2	Pre-Clinical	

DISCLAIMER:

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.

FOLLOWING

Protein Subunit	Spike-based (epitope screening)	ImmunoPrecise/LiteVax BV	SARS-CoV2	Pre-Clinical	
Replicating Viral Vector	YF17D Vector	KU Leuven	SARS-CoV2	Pre-Clinical	
Replicating Viral Vector	Measles Vector	Cadila Healthcare Limited	SARS-CoV2	Pre-Clinical	
Replicating Viral Vector	Measles Vector	Institute Pasteur/Themis/Univ. of Pittsburg Center for Vaccine Research/Merck	SARS-CoV2	Pre-Clinical	West Nile, Chik, Ebola, Lassa, Zika
Replicating Viral Vector	Measles Vector	FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo	SARS-CoV2	Pre-Clinical	
Replicating Viral Vector	Measles Virus (S, N targets)	DZIF – German Center for Infection Research/CanVirex AG	SARS-CoV2	Pre-clinical	Zika, H7N9, CHIKV
Replicating Viral Vector	Horsepox vector expressing S protein	Tonix Pharma/Southern Research	SARS-CoV2	Pre-Clinical	Smallpox, monkeypox
Replicating Viral Vector	Live viral vectored vaccine based on attenuated influenza virus backbone (intranasal)	BiOCAD and IEM	SARS-CoV2	Pre-Clinical	Influenza
Replicating Viral Vector	Recombinant vaccine based on Influenza A virus, for the prevention of COVID-19 (intranasal)	FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo	SARS-CoV2	Pre-Clinical	Influenza
Replicating Viral Vector	Attenuated Influenza expressing an antigenic portion of the Spike protein	Fundação Oswaldo Cruz and Instituto Buntantan	SARS-CoV2	Pre-Clinical	Influenza
Replicating Viral Vector	Influenza vector expressing RBD	University of Hong Kong	SARS-CoV2	Pre-Clinical	
Replicating Viral Vector	Replication-competent VSV chimeric virus technology (VSVΔG) delivering the SARS-CoV-2 Spike (S) glycoprotein.	IAVI/Merck	SARS-CoV2	Pre-Clinical	Ebola, Marburg, Lassa
Replicating Viral Vector	VSV-S	University of Western Ontario	SARS-CoV2	Pre-Clinical	HIV, MERS
Replicating Viral Vector	VSV vector	FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo	SARS-CoV2	Pre-Clinical	
Replicating Viral Vector	VSV-S	Israel Institute for Biological Research/Weizmann Institute of Science	SARS-CoV2	Pre-Clinical	
Replicating Viral Vector	M2-deficient single replication (M2SR) influenza vector	UW–Madison/FluGen/Bharat Biotech	SARS-CoV2	Pre-Clinical	influenza
Replicating Viral Vector	Newcastle disease virus vector (NDV-SARS-CoV-2/Spike)	Intravacc/ Wageningen Bioveterinary Research/Utrecht Univ.	SARS-CoV2	Pre-Clinical	
Replicating Viral Vector	Avian paramyxovirus vector (APMV)	The Lancaster University, UK	SARS-CoV2	Pre-Clinical	
RNA	mRNA	Selcuk University	SARS-CoV2	Pre-Clinical	
RNA	LNP-mRNA	Translate Bio/Sanofi Pasteur	SARS-CoV2	Pre-Clinical	
RNA	LNP-mRNA	CanSino Biologics/Precision NanoSystems	SARS-CoV2	Pre-Clinical	
RNA	LNP-encapsulated mRNA cocktail encoding VLP	Fudan University/ Shanghai JiaoTong University/RNACure Biopharma	SARS-CoV2	Pre-Clinical	
RNA	LNP-encapsulated mRNA encoding RBD	Fudan University/ Shanghai JiaoTong University/RNACure Biopharma	SARS-CoV2	Pre-Clinical	
RNA	Replicating Defective SARS-CoV-2 derived RNAs	Centro Nacional Biotecnología (CNB-CSIC), Spain	SARS-CoV2	Pre-Clinical	
RNA	LNP-encapsulated mRNA	University of Tokyo/ Daiichi-Sankyo	SARS-CoV2	Pre-Clinical	MERS

DISCLAIMER:

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.

FOLLOWING

RNA	Liposome-encapsulated mRNA	BIOCAD	SARS-CoV2	Pre-Clinical	
RNA	Several mRNA candidates	RNAimmune, Inc.	SARS-CoV2	Pre-Clinical	
RNA	mRNA	FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo	SARS-CoV2	Pre-Clinical	
RNA	mRNA	China CDC/Tongji University/Stermina	SARS-CoV2	Pre-Clinical	
RNA	mRNA	Arcturus/Duke-NUS	SARS-CoV2	Pre-Clinical	multiple candidates
RNA	LNP-mRNA	Chula Vaccine Research Center/University of Pennsylvania	SARS-CoV2	Pre-Clinical	
RNA	mRNA in an intranasal delivery system	eTheRNA	SARS-CoV2	Pre-Clinical	
RNA	mRNA	Greenlight Biosciences	SARS-CoV2	Pre-Clinical	
RNA	mRNA	IDIBAPS-Hospital Clinic, Spain	SARS-CoV2	Pre-Clinical	
VLP	VLP	Middle East Technical University	SARS-CoV2	Pre-Clinical	
VLP	Enveloped Virus-Like Particle (eVLP)	VBI Vaccines Inc.	SARS-CoV-2, SARS-CoV, & MERS-CoV	Pre-Clinical	CMV, GBM, Zika
VLP	S protein integrated in HIV VLPs	IrsiCaixa AIDS Research/IRTA-CReSA/Barcelona Supercomputing Centre/Grifols	SARS-CoV2	Pre-Clinical	
VLP	VLP + Adjuvant	Mahidol University/ The Government Pharmaceutical Organization (GPO)/Siriraj Hospital	SARS-CoV2	Pre-Clinical	
VLP	Virus-like particles, lentivirus and baculovirus vehicles	Navarrabiomed, Oncoimmunology group	SARS-CoV2	Pre-Clinical	
VLP	Virus-like particle, based on RBD displayed on virus-like particles	Saiba GmbH	SARS-CoV2	Pre-Clinical	
VLP	ADDomer™ multiepitope display	Imophoron Ltd and Bristol University's Max Planck Centre	SARS-CoV2	Pre-Clinical	
VLP	Unknown	Doherty Institute	SARS-CoV2	Pre-Clinical	
VLP	VLP	OSIVAX	SARS-CoV1 SARS-CoV2	Pre-Clinical	
VLP	eVLP	ARTES Biotechnology	SARS-CoV2	Pre-Clinical	malaria
VLP	VLPs peptides/whole virus	Univ. of Sao Paulo	SARS-CoV2	Pre-Clinical	
Unknown	Unknown	Tulane University	SARS-CoV2	Pre-Clinical	

DISCLAIMER:

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.

The time required to develop a new vaccine since the discovery of a new virus until the Marketing Authorization

At least 15 years

- **Identification of the virus** responsible for the epidemic: **1 year**
- **Development of a vaccine: 8 years**, according to Dr Frédéric Tangy in Paris-Match from 14-20 May 2020
- **Preclinical studies** :analytical, galenical, and toxicological in animals: **1 year**
- **Study in humans:**
 - **Phase I:** in **healthy volunteers** after favorable opinion of Protection Committee, and Free an Informed Consent of healthy voluntary subjects: **1 year**
 - **Phase II:** in **100 to 1000 subjects** after favorable opinion of Protection Committee and Free and Informed Consent of all subjects: **1 to 2 years**
 - **Phase III:** in **10 000 to 100 000 subjects or more** after favorable opinion of Protection Committee and Free and Informed Consent of all subjects: **2 years**

During development you cannot go from one study phase to the next, without having the results of the previous phase

Protocols for clinical studies of 2 Covid-19 vaccines

ChAdOx1 nCoV-19 and mRNA-1273 vaccines

(Written by the N.I.H.)

1- Protocol of the University of Oxford / Astra Zeneca Phase I study with the ChAdOx1 nCoV-19 vaccine

- **Sponsor** of the study: Research Services, University Offices Wellington Square, Oxford, 1200, United Kingdom
- **Country** of the study: **South Africa**
- **Summary of the study:** A Phase I/II, double-blinded, placebo-controlled, individually randomized trial to assess safety, immunogenicity and efficacy of the candidate Coronavirus disease (COVID-19) vaccine ChAdOx1 nCoV-19 in adults aged 18-65 years living with and without HIV in South Africa. The vaccine or placebo will be administered via an intramuscular injection into the deltoid muscle of the non dominant arm. A total of 2000 participants will be enrolled into the trial; 1950 HIV-uninfected and 50 people living with HIV. There will be 4 trial groups, group 1 (n=50; intensive safety & immunogenicity cohort, HIV negative), group 2a (n=250; safety, intense immunogenicity & efficacy), group 2b (n=1650; safety, immunogenicity & vaccine efficacy) and group 3 (n=50, intensive safety & immunogenicity cohort, HIV positive). Participants will be followed up for 12 months after enrollment.
- **Ethics Approval:** approval given on May, 21, 2020, by University of the Witwatersrand Human Research Ethics Committee Medical, 31 Princess of Wales Terrace, Parktown, Johannesburg, 2193, South Africa
- **2000 healthy** volunteer **subjects** aged **between 18** and **65 years**
- **Starting** of the study: **June 24, 2020**
- **End** of the study: **December 31, 2021**

Protocols for clinical studies of 2 Covid-19 vaccines

ChAdOx1 nCoV-19 and mRNA-1273 vaccines

(Written by the N.I.H.)

Following

2 - Protocol of the University of Oxford / Astra Zeneca Phase II / III study with the ChAdOx1 nCoV-19 vaccine

- **Title of the study:** A phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1nCoV-19
- **Country of the study:** **United-Kingdom**
- **Sponsor of the study:** Research Services, University Offices Wellington Square, Oxford, 1200, United Kingdom
- **Summary of the study:** To evaluate the efficacy of the candidate ChAdOx1nCoV-19 in adults aged 18 and over. To assess the safety of the ChAdOx1nCoV-19 vaccine candidate in adults and children. To assess the safety, tolerability and reactogenicity profile of the ChAdOx1 nCoV-19 candidate
- **Favorable opinion of the Competent Authority:** April 5, 2020
- **Favorable opinion of the Ethics Committee:** April 8, 2020
- **12 390 healthy volunteer subjects** divided into 4 age groups: **60** under the age of 18. **60** children aged between 2 and 11 years old. **12,030** adults aged between 18 and 64 years old. **240** subjects aged over 65
- **Starting of the study:** **May, 2020**
- **End of the study:** **May, 2021**

Protocols for clinical studies of 2 Covid-19 vaccines

ChAdOx1 nCoV-19 and mRNA-1273 vaccines

(Written by the N.I.H.)

Following

3- University of Oxford / Astra Zeneca Phase III study protocol with ChAdOx1 nCoV-19 vaccine

- **Title of the study:** A phase III randomized controlled trial to determine safety, efficacy, and immunogenicity of the non-replicating **ChAdOx1 nCoV-19 vaccine**
- **Country** of the study: **Brazil**
- **Ethics approval:** Approval pending:
 1. The National Commission for Research Ethics (Comissão Nacional de Ética em Pesquisa, (CONEP) - Brazil
 2. Oxford Tropical Research Ethics Committee (OxTREC) - UK
- **2000 healthy volunteer subjects aged between 18 and 55 years**
- **Starting** of the study: **May 1, 2020**
- **End** of the study: **July 31, 2021**

Protocols for clinical studies of 2 Covid-19 vaccines

ChAdOx1 nCoV-19 and mRNA-1273 vaccines

(Written by the N.I.H.)

Following

4- Protocol for Phase I study of Moderna with their new vaccine mRNA-1273

- **Title of the study:** Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV2 Infection COVID-19. This is a **phase I**, open-label, **dose-ranging clinical trial** in males and females, starting at 18 years of age
- **Sponsor of the study:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Country of the study:** **United States of America** (Georgia, Maryland, Washington)
- **Summary of the study:** This is a **phase I, open-label, dose-ranging clinical trial** in males and non-pregnant females, starting 18 years of age, inclusive, who are in good health and meet all eligibility criteria. This clinical trial is designed to assess the safety, reactogenicity and immunogenicity of mRNA-1273 manufactured by ModernaTX, Inc. mRNA-1273 is a novel lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine that encodes for a full-length, prefusion stabilized spike (S) protein of SARS-CoV-2. Enrollment will occur at up to 3 domestic clinical research sites. One hundred and fifty-five subjects will be enrolled into one of thirteen cohorts (10 micrograms [mcg], 25 mcg, 50 mcg, 100 mcg, and 250 mcg). Subjects will receive an intramuscular (IM) injection (0.5 milliliters [mL]) of mRNA-1273 on Days 1 and 29 in the deltoid muscle and will be followed through 12 months post second vaccination (Day 394). Follow-up visits will occur 1, 2, and 4 weeks post each vaccination (Days 8, 15, 29, 36, 43, and 57), as well as 3, 6, and 12 months post second vaccination (Days 119, 209, and 394).
- **Ethics approval:** ???
- **155 healthy volunteer** subjects aged **between 18 and 99** years
- **Starting** of the study: **March 16, 2020**
- **End** of the study: **November 22, 2021**

Protocols for clinical studies of 2 Covid-19 vaccines

ChAdOx1 nCoV-19 and mRNA-1273 vaccines

(Written by the N.I.H.)
Following

5- Protocol for Phase II study of Moderna with their new vaccine mRNA-1273

- **Title of the study:** A Phase 2a, Randomized, Observer-Blind, Placebo Controlled, Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 SARS-COV-2 Vaccine in Adults Aged 18 Years and Older
- **Sponsor** of the study: **Moderna TX, Inc.**
- **Collaborators:** Biomedical Advanced Research and Development Authority
- **Country** of the study: **United States of America .**
- **Locations:** Georgia, Kansas, Missouri, Nebraska, North Carolina, South Dakota, Texas, Utah.
- **Ethics approval:** Studies a U.S. FDA-regulated Drug Product ???
- **600 healthy** volunteer **subjects aged between 18 and 55+**
- **Starting** of the study: **May 20, 2020**
- **End** of the study: **August, 2021**

COVID-19 Vaccine: ChAdOx1 nCoV-19

According to information provided by the NIH and WHO, 160 vaccines against Covid-19 are under development. But, after reviewing Phase 1, 2 and 3 clinical studies, the protocols of which were all written by the NIH, and their advancement, we came to the following conclusion:

The only vaccine that has been developed and already manufactured for several months is the ChAdOx1 nCoV-19

All other 159 vaccines are "decoys"

ChAdOx1nCoV-19 is the result of a collaboration between the Institut Pasteur (Sanofi) and the Jenner Institute (AstraZeneca).

In ChAdOx1 nCoV-19, the genome of Covid-19 coronavirus is carried by the Chimpanzee adenovirus ChAdOx1, which serves as a viral vector

Manufacture of the ChAdOx1 nCoV-19 vaccine from 2018

Astra Zenecca manufactured the ChAdOx1 nCoV-19 vaccine from September 2018, which was the filing date of Microsoft's nanoparticles patent, US Patent WO 2020/060606 A1


Indeed, the protection of a patent occurs as soon as the patent is filed.

On the diagram on the next page, produced before 2020, the Astra Zenecca laboratory explains how it manufactures its ChAdOx1 nCoV-19 vaccine.

We are struck by the fact that the vaccine which results from the insertion of the Sars-CoV-2 genome into the genome of the vector virus ChAdOx1 **is called ChAdOx1 nCoV-19, whereas it should be called ChAdOx1 Sars-CoV -2.**


This scheme is deliberately misleading, because the Institut Pasteur wanted to hide the insertion of the AIDS virus in Sars-CoV-2, which they carried out between 2011 and 2015. **Indeed, the insertion of 4 HIV1 RNA sequences into the Sars-CoV2 genome leads to an artificial coronavirus Sars nCoV-19 , the number 19 indicating that the false pandemic was to be triggered with this artificial virus in 2019.**

COVID-19 Oxford Vaccine Trial



COVID-19 Vaccine: ChAdOx1 n-CoV-19

In the only vaccine developed and put into production, the genome of the Covid-19 coronavirus is carried by the Chimpanzee adenovirus ChAdOx1, which serves as a viral vector



ChAdOx1 nCoV-19: Covid-19 coronavirus carried by the vector virus **ChAdOx1**

Nanoparticles described in Microsoft Patent PCT/US2019/038084, which will control you thanks to 5G

Disinfectants: either **Thimerosal** or **Formaldehyde** and antibiotics

TREATMENT OF COVID-19 VIRAL INFECTION WITH HYDROXYCHLOROQUINE

Justification for the use of:

- Hydroxychloroquine
- Hydroxychloroquine and Azithromycin (or an antibiotic from the family of macrolides or tetracyclines): [see Documents 10 and 11](#)

Why Agnès BUZYN and Olivier VERAN have banned the prescription of Hydroxychloroquine to Covid-19 infected people ?

Agnès BUZYN and Yves LEVY know that DNA fragments from the germ of Malaria are inserted into the genome of Covid-19 (see [DOCUMENT 3](#))

Under these conditions, administration of hydroxychloroquine destroys the genome of Covid-19 and stops the infection.

Additional publications are communicated hereafter:

The full versions of the publications are available on the **website www.verite-covid19.fr**
and designated hereafter by **numbered Documents**

To read the full article see [DOCUMENT 10](#)

Therapeutic Drug Monitoring
13:496-501 © 1991 Raven Press, Ltd., New York

Pharmacokinetics of Quinine and Doxycycline in Patients with Acute Falciparum Malaria: A Study in Africa

*†‡§^{||}William Couet, †Roland Laroche, ‡Jean-Jacques Floch, *Bertrand Istin,
*Jean-Bernard Fourtillan, and §Jean-Frédéric Saunier

*CEMAF s.a., Poitiers, France; †Service des Maladies Infectieuses and ‡Laboratoire de Biochimie, CHU de Kamengue, Bujumbura, Burundi; and §Laboratoires Pfizer, Afrique et Proche Orient, Vitrolles and ^{||}INSEAD, Fontainebleau, France

Summary: The pharmacokinetics of quinine was investigated in patients with acute falciparum malaria treated with quinine alone or in the presence of doxycycline. Twenty-six patients divided into two groups of equal number were enrolled in the study. In the absence of doxycycline, the volume of distribution of quinine (mean \pm SD) was estimated to be 1.32 ± 0.32 L/kg, and its clearance was 0.125 ± 0.47 L/h/kg, which was only in partial agreement with previously published data. No effect of doxycycline on the pharmacokinetics of quinine was observed. **Key Words:** Acute falciparum malaria—Quinine—Doxycycline—Pharmacokinetics.

To read the full article see [DOCUMENT 11](#)

Gaillard et al. *Malar J* (2015) 14:445
DOI 10.1186/s12936-015-0980-0

Tetracyclines in malaria

Tiphaine Gaillard^{1,2,3}, Marylin Madamet^{2,4,5} and Bruno Pradines^{1,2,5,6*}

Abstract

Malaria, a parasite vector-borne disease, is one of the greatest health threats in tropical regions, despite the availability of malaria chemoprophylaxis. The emergence and rapid extension of *Plasmodium falciparum* resistance to various anti-malarial drugs has gradually limited the number of potential malaria therapeutics available to clinicians. In this context, doxycycline, a synthetically derived tetracycline, constitutes an interesting alternative for malaria treatment and prophylaxis. Doxycycline is a slow-acting blood schizontocidal agent that is highly effective at preventing malaria. In areas with chloroquine and multidrug-resistant *P. falciparum* parasites, doxycycline has already been successfully used in combination with quinine to treat malaria, and it has been proven to be effective and well-tolerated. Although not recommended for pregnant women and children younger than 8 years of age, severe adverse effects are rarely reported. In addition, resistance to doxycycline is rarely described. Prophylactic and clinical failures of doxycycline have been associated with both inadequate doses and poor patient compliance. The effects of tetracyclines on parasites are not completely understood. A better comprehension of the mechanisms underlying drug resistance would facilitate the identification of molecular markers of resistance to predict and survey the emergence of resistance.

Keywords: Malaria, *Plasmodium falciparum*, Anti-malarial drug, Resistance, Tetracycline, Doxycycline, Prophylaxis, Treatment

1-Unité de Parasitologie, Département d'infectiologie de terrain, Institut de Recherche Biomédicale des Armées, Marseille, France. 2-Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes, UM 63, CNRS 7278, IRD 198, Inserm 1095, Aix Marseille Université, Marseille, France. 3-Fédération des Laboratoires, Hôpital d'Instruction des Armées Sainte Anne, Toulon, France. 4-Equipe Résidente de Recherche en Infectiologie Tropicale, Institut de Recherche Biomédicale des Armées, Marseille, France. 5-Centre National de Référence du Paludisme, Marseille, France. 6-Unité de Parasitologie et d'Entomologie, Département des Maladies Infectieuses, Institut de Recherche Biomédicale des Armées, Brétigny sur Orge, France.

To read the full article see [DOCUMENT 5](#)

ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice



Naif Khalaf Alharbi^{a,b,*}, Eriko Padron-Regalado^a, Craig P. Thompson^{a,c}, Alexandra Kupke^{d,e}, Daniel Wells^a, Megan A. Sloan^a, Keith Grehan^f, Nigel Temperton^f, Teresa Lambe^a, George Warimwe^a, Stephan Becker^{d,e}, Adrian V.S. Hill^a, Sarah C. Gilbert^a

^aThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK

^bKing Abdullah International Medical Research Center, Riyadh, Saudi Arabia

^cDepartment of Zoology, University of Oxford, Oxford, UK

^dInstitute of Virology, Philipps University of Marburg, Marburg, Germany

^eGerman Center for Infection Research, TTU Emerging Infections, Germany

^fViral Pseudotype Unit, School of Pharmacy, University of Kent, Chatham Maritime, Kent ME4 4TB, UK

ARTICLE INFO

Article history:

Received 2 March 2017

Received in revised form 30 April 2017

Accepted 10 May 2017

Available online 1 June 2017

Keywords:

Coronavirus

MERS-CoV

ChAdOx1

Adenoviral vector

MVA

Poxviral vector

Vaccine

Prime boost

Vaccination

Immunogenicity

ABSTRACT

The Middle East respiratory syndrome coronavirus (MERS-CoV) has infected more than 1900 humans, since 2012. The syndrome ranges from asymptomatic and mild cases to severe pneumonia and death. The virus is believed to be circulating in dromedary camels without notable symptoms since the 1980s. Therefore, dromedary camels are considered the only animal source of infection. Neither antiviral drugs nor vaccines are approved for veterinary or medical use despite active research on this area. Here, we developed four vaccine candidates against MERS-CoV based on ChAdOx1 and MVA viral vectors, two candidates per vector. All vaccines contained the full-length spike gene of MERS-CoV; ChAdOx1 MERS vaccines were produced with or without the leader sequence of the human tissue plasminogen activator gene (tPA) where MVA MERS vaccines were produced with tPA, but either the mH5 or F11 promoter driving expression of the spike gene. All vaccine candidates were evaluated in a mouse model in prime only or prime-boost regimens. ChAdOx1 MERS with tPA induced higher neutralising antibodies than ChAdOx1 MERS without tPA. A single dose of ChAdOx1 MERS with tPA elicited cellular immune responses as well as neutralising antibodies that were boosted to a significantly higher level by MVA MERS. The humoral immunogenicity of a single dose of ChAdOx1 MERS with tPA was equivalent to two doses of MVA MERS (also with tPA). MVA MERS with mH5 or F11 promoter induced similar antibody levels; however, F11 promoter enhanced the cellular immunogenicity of MVA MERS to significantly higher magnitudes. In conclusion, our study showed that MERS-CoV vaccine candidates could be optimized by utilising different viral vectors, various genetic designs of the vectors, or different regimens to increase immunogenicity. ChAdOx1 and MVA vectored vaccines have been safely evaluated in camels and humans and these MERS vaccine candidates should now be tested in camels and in clinical trials.

© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Correlation Between Relative Nasopharyngeal Virus RNA Load and Lymphocyte Count Disease Severity in Patients with COVID-19

Yang Liu,^{1,*} Wenjian Liao,^{2,*} Lagen Wan,¹ Tianxing Xiang,³ and Wei Zhang²

Abstract

The aim of this study was to analyze the correlation between dynamic changes in the nasopharyngeal viral load of patients infected with the new coronavirus causing pneumonia and lymphocyte count disease severity. Cases newly diagnosed with COVID-19 at the First Affiliated Hospital of Nanchang University from January 2020 to February 2020 were analyzed retrospectively. Quantitative real-time polymerase chain reaction was used to determine severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from throat swab sample Δ CT values; lymphocyte and lymphocyte subset counts, coagulation system factor levels, myocardial injury indexes, and laboratory biochemical indicators were compared between the mild group and the severe group. The correlation between the relative load of nasopharyngeal SARS-CoV-2 RNA and severe disease symptoms was analyzed. Of the 76 patients, 49 were male and 27 were female. The lymphocyte, CD4⁺ T lymphocyte, and CD8⁺ T lymphocyte counts all differed significantly between the two groups ($p < 0.001$), as did differences in interleukin (IL)-2R, IL-6, and IL-8 levels ($p = 0.022$, 0.026 , and 0.012 , respectively). Moreover, there were significant differences in prothrombin time, D-dimer, and fibrinogen levels between the mild group and the severe group ($p = 0.029$, 0.006 , and < 0.001 , respectively), and in lactate dehydrogenase and troponin ($p < 0.001$ and $p = 0.007$, respectively). SARS-CoV-2 RNA load and lymphocyte count, CD4⁺ T lymphocyte count, and CD8⁺ T lymphocyte count were linearly negatively correlated ($p < 0.001$). SARS-CoV-2 RNA load was positively correlated with IL-2R, prothrombin time, lactate dehydrogenase, and hypersensitive troponin T ($p = 0.002$, $p = 0.009$, and $p < 0.001$, respectively). In addition, the time that it took for the nucleic acid test to turn negative was significantly shorter for patients in the mild group than for those in the severe group ($Z = -6.713$, $p < 0.001$). In conclusion, relative SARS-CoV-2 RNA load in the nasopharynx is closely related to COVID-19 severity. If the relative RNA load was higher, the lymphocyte count was lower, organ damage was greater, and the time it took for the nucleic acid test to turn negative was longer.

Keywords: nasopharyngeal virus RNA load, COVID-19, lymphocyte count, organ damage

Interview with Bill Gates Paris-Match April 16-22, 2020
Bill Gates-doctor of the world

To read this interview, see [DOCUMENTS 7 and 8](#)